International Stem Cell (ISCO) 10-Q 13 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 01, 2013
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'ISCO	'
Entity Registrant Name	'International Stem Cell CORP	'
Entity Central Index Key	'0001355790	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	149,224,387

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
Assets	'	'
Cash and cash equivalents	$1,792,000	$654,000
Accounts receivable, net of allowance for doubtful accounts of $19 and $4 at September 30, 2013 and December 31, 2012, respectively	398,000	273,000
Inventory, net	1,360,000	1,199,000
Prepaid expenses and other current assets	407,000	456,000
Restricted cash	50,000	'
Total current assets	4,007,000	2,582,000
Property and equipment, net	851,000	1,134,000
Intangible assets, net	2,036,000	1,634,000
Deposits and other assets	33,000	20,000
Total assets	6,927,000	5,370,000
Liabilities, Redeemable Preferred Stock and Stockholders' Equity (Deficit)	'	'
Accounts payable	522,000	969,000
Accrued liabilities	1,056,000	730,000
Deferred revenue	156,000	233,000
Related party payable	16,000	5,000
Advances	250,000	250,000
Fair value of warrant liability	4,389,000	'
Total current liabilities	6,389,000	2,187,000
Commitments and contingencies	'	'
Stockholders' Equity (Deficit)	'	'
Common stock, $0.001 par value, 300,000,000 shares authorized, 134,169,565 and 87,388,815 issued and outstanding at September 30, 2013 and December 31, 2012, respectively	134,000	87,000
Additional paid-in capital	74,967,000	69,945,000
Deficit accumulated during the development stage	-79,504,000	-71,792,000
Total stockholders' deficit	-4,403,000	-1,758,000
Total liabilities, redeemable preferred stock and stockholders' equity (deficit)	6,927,000	5,370,000
Series G Preferred Stock [Member]	'	'
Liabilities, Redeemable Preferred Stock and Stockholders' Equity (Deficit)	'	'
Convertible Redeemable Preferred stock	4,941,000	4,941,000
Series C Preferred Stock [Member]	'	'
Stockholders' Equity (Deficit)	'	'
Preferred stock	'	$2,000

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified
Allowance for doubtful accounts receivable	$19	$4
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	134,169,565	87,388,815
Common stock, shares outstanding	134,169,565	87,388,815
Series G Preferred Stock [Member]	'	'
Convertible Redeemable Preferred stock, par value	$0.00	$0.00
Convertible Redeemable Preferred stock, shares authorized	5,000,000	5,000,000
Convertible Redeemable Preferred stock, shares issued	5,000,000	5,000,000
Convertible Redeemable Preferred stock, shares outstanding	5,000,000	5,000,000
Convertible Redeemable Preferred stock, Liquidation preference	$5,000	$5,000
Series D Preferred Stock [Member]	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	50	50
Preferred stock, shares issued	43	43
Preferred Stock, shares outstanding	43	43
Liquidation preference	$4,320	$4,320
Series B Preferred Stock [Member]	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	300,000	300,000
Preferred Stock, shares outstanding	300,000	300,000
Liquidation preference	$397	$385
Series C Preferred Stock [Member]	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	0	3,000,000
Preferred stock, shares issued	0	2,000,000
Preferred Stock, shares outstanding	0	2,000,000
Liquidation preference	$0	$2,507

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended		145 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Revenues	'	'	'	'	'
Product sales	$1,670	$1,187	$4,412	$3,320	$16,610
Royalties and license	'	'	'	'	135
Total revenue	1,670	1,187	4,412	3,320	16,745
Development expenses	'	'	'	'	'
Cost of sales	447	320	1,110	957	5,716
Research and development	932	900	2,627	2,702	24,520
Marketing	632	477	1,823	1,521	7,762
General and administrative	1,362	1,570	4,461	5,364	43,589
Total development expenses	3,373	3,267	10,021	10,544	81,587
Loss from development activities	-1,703	-2,080	-5,609	-7,224	-64,842
Other income (expense)	'	'	'	'	'
Settlement with related company	'	'	'	'	-93
Miscellaneous expense	'	-1	-20	-55	-265
Dividend income	'	'	'	'	94
Interest expense	'	'	'	'	-2,225
Sublease income	5	'	18	7	334
Fair value of warrant liability in excess of proceeds	-1,390	'	-1,390	'	-1,390
Financing transaction costs	-738	'	-738	'	-738
Change in fair value of warrant liability	27	'	27	38	-1,330
Total other expense, net	-2,096	-1	-2,103	-10	-5,613
Loss before income taxes	-3,799	-2,081	-7,712	-7,234	-70,455
Provision for income taxes	'	'	'	'	7
Net loss	-3,799	-2,081	-7,712	-7,234	-70,462
Deemed dividend on preferred stock	'	'	'	-1,375	-1,375
Dividends on preferred stock	'	93	'	-129	-8,097
Net loss attributable to common stockholders	($3,799)	($1,988)	($7,712)	($8,738)	($79,934)
Net loss per common share-basic and diluted	($0.03)	($0.02)	($0.07)	($0.10)	'
Weighted average shares-basic and diluted	128,243	87,350	114,830	85,421	'

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock, Members' Deficit and Stockholders' Equity (Deficit) (USD $)

Total

Series G Preferred Stock [Member]

Series A Preferred Stock [Member]

Series B Preferred Stock [Member]

Series D Preferred Stock [Member]

Redeemable Convertible Preferred Stock [Member]

Common Stock [Member]

Common Stock [Member]

Preferred Stock [Member]

Preferred Stock [Member]

Preferred Stock [Member]

Preferred Stock [Member]

Preferred Stock [Member]

Preferred Stock [Member]

Note Subscription on Perpetual Preferred [Member]

Subscription Receivable on Common Stock [Member]

Additional Paid-in Capital [Member]

Deficit Accumulated During the Development Stage [Member]

Members' Deficit [Member]

USD ($)

USD ($)

USD ($)

Series G Preferred Stock [Member]

USD ($)

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series B Preferred Stock [Member]

Series C Preferred Stock [Member]

Series D Preferred Stock [Member]

Series E Preferred Stock [Member]

Series F Preferred Stock [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Beginning balance at Aug. 17, 2001

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Members contribution

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$100,000

Net loss

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-141,000

Ending balance at Dec. 31, 2001

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-41,000

Ending balance, Shares at Dec. 31, 2001

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Members contribution

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

250,000

Net loss

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-391,000

Ending balance at Dec. 31, 2002

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-182,000

Ending balance, Shares at Dec. 31, 2002

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Members contribution

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

195,000

Net loss

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-519,000

Ending balance at Dec. 31, 2003

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-506,000

Ending balance, Shares at Dec. 31, 2003

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Members contribution

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,110,000

Net loss

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-854,000

Ending balance at Dec. 31, 2004

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-250,000

Ending balance, Shares at Dec. 31, 2004

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Members contribution

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

780,000

Net loss

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-1,386,000

Ending balance at Dec. 31, 2005

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-856,000

Ending balance, Shares at Dec. 31, 2005

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Effect of the Reorganization Transactions

-606,000

'

'

'

'

'

20,000

'

'

'

'

'

'

'

'

'

2,665,000

-3,291,000

606,000

Members contribution

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

250,000

Effect of the Reorganization Transactions, Shares

'

'

'

'

'

'

20,000,000

'

'

'

'

'

'

'

'

'

'

'

'

BTHC transactions

'

'

'

'

'

'

2,000

'

'

'

'

'

'

'

'

'

-2,000

'

'

BTHC transactions, Shares

'

'

'

'

'

'

2,210,000

'

'

'

'

'

'

'

'

'

'

'

'

Offering costs

-2,778,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-2,778,000

'

'

Common stock issued for services

1,350,000

'

'

'

'

'

1,000

'

'

'

'

'

'

'

'

'

1,349,000

'

'

Warrants issued for equity placement services

1,231,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,231,000

'

'

Common stock issued for services, Shares

'

'

'

'

'

'

1,350,000

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock

10,382,000

'

'

'

'

'

11,000

'

'

'

'

'

'

'

'

'

10,371,000

'

'

Warrants issued with promissory note

638,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

638,000

'

'

Issuance of common stock, Shares

'

'

'

'

'

'

10,437,000

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

842,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

842,000

'

'

Warrants issued for services

222,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

222,000

'

'

Net loss

-6,584,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-6,584,000

'

Ending balance at Dec. 31, 2006

4,697,000

'

'

'

'

'

34,000

'

'

'

'

'

'

'

'

'

14,538,000

-9,875,000

'

Ending balance, Shares at Dec. 31, 2006

'

'

'

'

'

'

33,997,000

'

'

'

'

'

'

'

'

'

'

'

'

Offering costs

-382,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-382,000

'

'

Warrants issued for equity placement services

169,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

169,000

'

'

Issuance of common stock

1,370,000

'

'

'

'

'

1,000

'

'

'

'

'

'

'

'

'

1,369,000

'

'

Issuance of common stock, Shares

'

'

'

'

'

'

1,370,000

'

'

'

'

'

'

'

'

'

'

'

'

From exercise of warrants

3,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,000

'

'

From exercise of warrants, Shares

'

'

'

'

'

'

3,000

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

427,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

427,000

'

'

Net loss

-6,072,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-6,072,000

'

Ending balance at Dec. 31, 2007

212,000

'

'

'

'

'

35,000

'

'

'

'

'

'

'

'

'

16,124,000

-15,947,000

'

Ending balance, Shares at Dec. 31, 2007

'

'

'

'

'

'

35,370,000

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of Preferred Stock

4,550,000

'

'

'

'

'

'

'

1,000

1,000

2,000

'

'

'

'

'

4,546,000

'

'

Issuance of Preferred Stock, Shares

'

'

'

'

'

'

'

'

1,000,000

550,000

2,000,000

'

'

'

'

'

'

'

'

Warrants issued and beneficial conversion feature

911,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

911,000

'

'

Common stock issued for services

596,000

'

'

'

'

'

3,000

'

'

'

'

'

'

'

'

'

593,000

'

'

Common stock issued for services, Shares

'

'

'

'

'

'

3,041,000

'

'

'

'

'

'

'

'

'

'

'

'

Deemed Dividend

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,582,000

-1,582,000

'

Stock-based compensation

735,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

735,000

'

'

Net loss

-6,571,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-6,571,000

'

Ending balance at Dec. 31, 2008

433,000

'

'

'

'

'

38,000

'

1,000

1,000

2,000

'

'

'

'

'

24,491,000

-24,100,000

'

Ending balance, Shares at Dec. 31, 2008

'

'

'

'

'

'

38,411,000

'

1,000,000

550,000

2,000,000

'

'

'

'

'

'

'

'

Accrued and paid dividend on preferred stock

'

'

'

'

2,480,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending balance at Sep. 30, 2009

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Beginning balance at Dec. 31, 2008

433,000

'

'

'

'

'

38,000

'

1,000

1,000

'

'

'

'

'

'

24,491,000

-24,100,000

'

Beginning balance, Shares at Dec. 31, 2008

'

'

'

'

'

'

38,411,000

'

1,000,000

550,000

'

'

'

'

'

'

'

'

'

Issuance of Preferred Stock

3,682,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,682,000

'

'

Preferred Stock Subscription

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for services

942,000

'

'

'

'

'

1,000

'

'

'

'

'

'

'

'

'

941,000

'

'

Common stock issued for services, Shares

'

'

'

'

'

'

1,208,000

'

'

'

'

'

'

'

'

'

'

'

'

From conversion of debt, Shares

'

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

From conversion of preferred stock

'

'

'

'

'

'

4,000

'

'

-1,000

'

'

'

'

'

'

-3,000

'

'

From conversion of preferred stock, Shares

'

'

'

'

'

'

3,727,000

'

-400,000

-150,000

'

'

'

'

'

'

'

'

'

From conversion of debt

500,000

'

'

'

'

'

2,000

'

'

'

'

'

'

'

'

'

498,000

'

'

From cashless exercise of warrants

283,000

'

'

'

'

'

4,000

'

'

'

'

'

'

'

'

'

279,000

'

'

From cashless exercise of warrants, Shares

'

'

'

'

'

'

3,510,000

'

'

'

'

'

'

'

'

'

'

'

'

From exercise of warrants

963,000

'

'

'

'

'

4,000

'

'

'

'

'

'

'

-2,700,000

'

3,659,000

'

'

From exercise of warrants, Shares

'

'

'

'

'

'

4,392,000

'

'

'

'

'

'

'

'

'

'

'

'

Cumulative effect adjustment-warrant liabilities

-1,274,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-1,704,000

430,000

'

Equity placement shares

-250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-250,000

'

'

Deemed Dividend

-869,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,163,000

-4,032,000

'

Issuance of common stock, for cash

1,400,000

'

'

'

'

'

3,000

'

'

'

'

'

'

'

'

'

1,397,000

'

'

Options issued for services

106,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

106,000

'

'

Issuance of common stock, for cash, Shares

'

'

'

'

'

'

2,787,000

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

410,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

410,000

'

'

Warrants issued for services

281,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

281,000

'

'

Deemed dividend on preferred stock

-364,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-364,000

'

Net loss

-8,513,000

'

'

'

'

'

'

'

'

'

'

'

'

'

-9,000

'

'

-8,504,000

'

Ending balance at Dec. 31, 2009

-2,270,000

'

'

'

'

'

56,000

'

1,000

'

2,000

'

'

'

-2,709,000

'

36,950,000

-36,570,000

'

Ending balance, Shares at Dec. 31, 2009

'

'

'

'

'

'

56,035,000

'

600,000

400,000

2,000,000

'

'

'

'

'

'

'

'

Preferred Stock Subscription, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000

'

'

'

'

'

Preferred Stock Subscription

0

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

From conversion of preferred stock and options

'

'

'

'

'

'

1,000

'

'

'

'

'

'

'

'

'

-1,000

'

'

From conversion of preferred stock and options, Shares

'

'

'

'

'

'

800,000

'

-100,000

-100,000

'

'

'

-1,000

'

'

'

'

'

Common stock issued for services

1,085,000

'

'

'

'

'

1,000

'

'

'

'

'

'

'

'

'

1,084,000

'

'

Common stock issued for services, Shares

'

'

'

'

'

'

749,000

'

'

'

'

'

'

'

'

'

'

'

'

From cashless exercise of warrants and options

1,538,000

'

'

'

'

'

2,000

'

'

'

'

'

'

'

'

'

1,536,000

'

'

From conversion of debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

From cashless exercise of warrants and options, Shares

'

'

'

'

'

'

1,531,000

'

'

'

'

'

'

'

'

'

'

'

'

From exercise of warrants

1,493,000

'

'

'

'

'

5,000

'

'

'

'

'

'

'

-3,254,000

-5,000

4,747,000

'

'

From exercise of warrants, Shares

'

'

'

'

'

'

5,063,000

'

'

'

'

'

'

'

'

'

'

'

'

Warrants reclassified to equity

805,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

805,000

'

'

Accrued and paid dividend on preferred stock

-524,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-524,000

'

Swap notes Receivable and Perpetual Preferred Stock

4,763,000

'

'

'

'

'

'

'

'

'

'

'

'

'

5,963,000

'

-1,200,000

'

'

Issuance of common stock, for cash

10,190,000

'

'

'

'

'

10,000

'

'

'

'

'

'

'

'

'

10,181,000

'

'

Options issued for services

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock, for cash, Shares

'

'

'

'

'

'

10,593,000

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

2,068,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,068,000

'

'

Warrants issued for services

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deemed dividend on preferred stock

-1,037,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-1,037,000

'

Net loss

-12,723,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-12,723,000

'

Ending balance at Dec. 31, 2010

5,389,000

'

'

'

'

'

75,000

'

1,000

'

2,000

'

'

0

'

-5,000

56,170,000

-50,854,000

'

Ending balance, Shares at Dec. 31, 2010

'

'

'

'

'

'

74,771,000

'

500,000

300,000

2,000,000

'

'

'

'

'

'

'

'

From exercise of options and warrants

527,000

'

'

'

'

'

1,000

'

'

'

'

'

'

'

'

'

526,000

'

'

From exercise of options and warrants, Shares

'

'

'

'

'

'

1,060,000

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for services

303,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

303,000

'

'

Common stock issued for services, Shares

'

'

'

'

'

'

150,000

'

'

'

'

'

'

'

'

'

'

'

'

From cashless exercise of warrants

26,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

26,000

'

'

Stock subscription

5,000

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000

'

'

'

'

From cashless exercise of warrants, Shares

'

'

'

'

'

'

55,000

'

'

'

'

'

'

'

'

'

'

'

'

Accrued dividend on preferred stock

-430,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-430,000

'

Issuance of common stock, for cash

3,358,000

'

'

'

'

'

4,000

'

'

'

'

'

'

'

'

'

3,354,000

'

'

Issuance of common stock, for cash, Shares

'

'

'

'

'

'

4,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

3,541,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,541,000

'

'

Warrants issued for services

75,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

75,000

'

'

Net loss

-9,171,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-9,171,000

'

Ending balance at Dec. 31, 2011

3,623,000

'

'

'

'

'

80,000

'

'

'

2,000

'

'

0

'

'

63,995,000

-60,455,000

'

Ending balance, Shares at Dec. 31, 2011

'

'

'

'

'

'

80,036,000

'

'

300,000

2,000,000

'

'

'

'

'

'

'

'

Warrants issued with promissory note

73,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reversal of dividend accreted

93,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued dividend on preferred stock

129,000

0

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock, for cash

2,088,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants issued for services

-73,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deemed dividend on preferred stock

1,375,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-7,234,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending balance at Sep. 30, 2012

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Beginning balance at Dec. 31, 2011

3,623,000

'

'

'

'

'

80,000

'

1,000

'

2,000

'

'

0

'

'

63,995,000

-60,455,000

'

Beginning balance, Shares at Dec. 31, 2011

'

'

'

'

'

'

80,036,000

'

500,000

300,000

2,000,000

'

'

'

'

'

'

'

'

Issuance of convertible redeemable Series G preferred stock, net of issuance costs of $59, value

'

'

'

'

'

4,941,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of convertible redeemable Series G preferred stock, net of issuance costs of $59, shares

'

'

'

'

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Beneficial conversion feature for Series G preferred stock

1,375,000

'

'

'

'

-1,375,000

'

'

'

'

'

'

'

'

'

'

1,375,000

'

'

Common stock issued for services

59,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

59,000

'

'

Common stock issued for services, Shares

'

'

'

'

'

'

335,000

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

From conversion of preferred stock

'

'

'

'

'

'

2,000

'

-1,000

'

'

'

'

'

'

'

-1,000

'

'

From conversion of preferred stock, Shares

'

'

'

'

'

'

2,000,000

'

-500,000

'

'

'

'

'

'

'

'

'

'

From exercise of options

4,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,000

'

'

From exercise of options, shares

'

'

'

'

'

'

18,000

'

'

'

'

'

'

'

'

'

'

'

'

Reversal of dividend accreted

93,000

93,000

'

'

'

-93,000

'

'

'

'

'

'

'

'

'

'

'

93,000

'

Accrued dividend on preferred stock

-222,000

'

'

'

0

93,000

'

'

'

'

'

'

'

'

'

'

'

-222,000

'

Issuance of common stock, for cash

2,084,000

'

'

'

'

'

5,000

'

'

'

'

'

'

'

'

'

2,079,000

'

'

Issuance of common stock, for cash, Shares

'

'

'

'

'

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

2,361,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,361,000

'

'

Warrants issued for services

73,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

73,000

'

'

Deemed dividend on preferred stock

-1,375,000

'

'

'

'

1,375,000

'

'

'

'

'

'

'

'

'

'

'

-1,375,000

'

Net loss

-9,833,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-9,833,000

'

Ending balance at Dec. 31, 2012

-1,758,000

'

'

'

'

4,941,000

87,000

'

'

'

2,000

'

'

'

'

'

69,945,000

-71,792,000

'

Ending balance, Shares at Dec. 31, 2012

'

'

'

'

'

5,000,000

87,389,000

'

'

300,000

2,000,000

'

'

'

'

'

'

'

'

Common stock issued for services

180,000

'

'

'

'

'

1,000

'

'

'

'

'

'

'

'

'

179,000

'

'

Common stock issued for services, Shares

'

'

'

'

'

'

755,000

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock

3,285,000

'

'

'

'

'

36,000

'

'

'

'

'

'

'

'

'

3,249,000

'

'

From conversion of preferred stock

'

'

'

'

'

'

8,000

'

'

'

-2,000

'

'

'

'

'

-6,000

'

'

Warrants issued with promissory note

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

From conversion of preferred stock, Shares

'

'

'

'

'

'

8,000,000

'

'

'

-2,000,000

'

'

'

'

'

'

'

'

From exercise of warrants

311,000

'

'

'

'

'

2,000

'

'

'

'

'

'

'

'

'

309,000

'

'

From exercise of warrants, Shares

'

'

'

'

'

'

1,700,000

'

'

'

'

'

'

'

'

'

'

'

'

Accrued dividend on preferred stock

'

0

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock, for cash

6,289,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock, for cash, Shares

'

'

'

'

'

'

36,325,000

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

1,291,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,291,000

'

'

Net loss

-7,712,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-7,712,000

'

Ending balance at Sep. 30, 2013

($4,403,000)

'

'

'

'

$4,941,000

$134,000

'

'

'

'

'

'

'

'

'

$74,967,000

($79,504,000)

'

Ending balance, Shares at Sep. 30, 2013

'

'

'

'

'

5,000,000

134,169,000

'

'

300,000

'

'

'

'

'

'

'

'

'

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock, Members' Deficit and Stockholders' Equity (Deficit) (Parenthetical) (USD $)	12 Months Ended	9 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012	Sep. 30, 2013
	Redeemable Convertible Preferred Stock [Member]	Common Stock [Member]
	Series G Preferred Stock [Member]
Issuance cost on issue of convertible redeemable Series G preferred stock	$59	'
Issuance of common stock, issuance costs	'	$23

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended		145 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Cash flows from operating activities	'	'	'
Net loss	($7,712)	($7,234)	($70,462)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Depreciation and amortization	347	369	2,263
Accretion of discount on notes payable	'	'	103
Accretion of discount on bridge loans	'	'	638
Warrants issued for services	'	73	370
Non-cash compensation expense	1,291	1,760	12,062
Common stock issued for services	180	30	4,536
Fair value of warrant liability in excess of proceeds	1,390	'	1,390
Financing transaction costs including cash and warrants	738	'	738
Change in fair value of warrant liability	-27	-38	1,330
Amortization of discount on convertible debt	'	'	1,081
Allowance for doubtful accounts	22	'	26
Allowance for inventory obsolescence	40	-23	76
Interest on perpetual preferred stock notes receivable	'	'	-35
Loss on disposal of fixed assets	16	50	96
Impairment of intangible assets	32	23	221
Changes in operating assets and liabilities:	'	'	'
(Increase) decrease in accounts receivable	-148	-271	-421
(Increase) decrease in inventory	-201	169	-1,436
(Increase) decrease in prepaid assets and other assets	49	-19	-407
(Increase) decrease in restricted cash	-50	'	-50
(Increase) decrease in deposits	-13	-4	-33
Increase (decrease) in accounts payable	-447	279	630
Increase (decrease) in accrued expenses	326	-287	1,341
Increase (decrease) in deferred revenue	-77	-13	156
Increase (decrease) in related party payable	11	17	-149
Net cash used in operating activities	-4,233	-5,119	-45,936
Investing activities	'	'	'
Purchases of property and equipment	-34	-197	-2,720
Proceeds from sale of fixed assets	'	7	7
Payments for patent licenses and trademarks	-480	-440	-2,757
Net cash used in investing activities	-514	-630	-5,470
Financing activities	'	'	'
Proceeds from Members' contributions	'	'	2,685
Proceeds from issuance of common stock	6,289	2,088	35,171
Proceeds from issuance of preferred stock	'	4,941	17,202
Proceeds from issuance of convertible promissory notes	'	'	2,100
Proceeds from exercise of warrants and options	242	'	1,234
Payment of preferred stock dividends	'	-237	-1,320
Payment of promissory notes	'	'	-2,203
Payment of offering costs	-646	'	-2,406
Proceeds from convertible debt, advances and loan payable	'	'	1,360
Payment of loan payable	'	'	-625
Net cash provided by financing activities	5,885	6,792	53,198
Net increase in cash and cash equivalents	1,138	1,043	1,792
Cash and cash equivalents, beginning of period	654	1,337	'
Cash and cash equivalents, end of period	1,792	2,380	1,792
Supplemental disclosures of cash flow information:	'	'	'
Cash paid for interest	2	'	374
Cash paid for income taxes	'	'	11
Non-cash financing activities:	'	'	'
Discount on convertible debt from beneficial conversion feature	'	'	641
Discount on convertible debt from warrants	'	'	270
Accretion of preferred stock dividends	'	93	93
Deemed dividend on preferred stock	'	1,375	8,058
Reversal of preferred dividends accreted	'	-93	-93
Conversion of debt to common stock	'	'	500
Warrants issued for placement agent services	115	'	1,346
Warrants issued with promissory notes	'	'	638
Non-cash sale of preferred stock	'	'	382
Dividend on preferred stock exchanged for note receivable	'	'	95
Conversion of preferred stock	'	'	2
Cashless exercise of warrants	'	'	$1,847

Organization_and_Significant_A

Organization and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Organization and Significant Accounting Policies	'
	1. Organization and Significant Accounting Policies
	Business Combination and Corporate Restructure
	BTHC III, Inc. (“BTHC III” or the “Company”) was organized in Delaware in June 2005 as a shell company to effect the reincorporation of BTHC III, LLC, a Texas limited liability company. On December 28, 2006, the Company effected a Share Exchange pursuant to which it acquired all of the stock of International Stem Cell Corporation, a California corporation (“ISC California”). After giving effect to the Share Exchange, the stockholders of ISC California owned 93.7% of issued and outstanding shares of common stock. As a result of the Share Exchange, ISC California is now a wholly-owned subsidiary, though for accounting purposes it was deemed to have been the acquirer in a “reverse merger.” In the reverse merger, BTHC III is considered the legal acquirer and ISC California is considered the accounting acquirer. On January 29, 2007, the Company changed its name from BTHC III, Inc. to International Stem Cell Corporation.
	Lifeline Cell Technology, LLC (“LCT”) was formed in the State of California on August 17, 2001. LCT is in the business of developing and manufacturing purified primary human cells and optimized reagents for cell culture. LCT’s scientists have used a technology, called basal medium optimization, to systematically produce products designed to culture specific human cell types and to elicit specific cellular behaviors. These techniques also produce products that do not contain non-human animal proteins, a feature desirable to the research and therapeutic markets. LCT distinguishes itself in the industry by having in place scientific and manufacturing staff with the experience and knowledge to set up systems and facilities to produce a source of consistent, standardized, non-human animal protein free cell products, some of which are suitable for FDA approval.
	On July 1, 2006, LCT entered into an agreement among LCT, ISC California and the holders of membership units and warrants. Pursuant to the terms of the agreement, all the membership units in LCT were exchanged for 20,000,000 shares of ISC California common stock and for ISC California’s assumption of LCT’s obligations under the warrants. LCT became a wholly-owned subsidiary of ISC California.
	Lifeline Skin Care, Inc. (“LSC”) was formed in the State of California on June 5, 2009 and is a wholly-owned subsidiary of ISC California. LSC develops, manufactures and markets cosmeceutical products, utilizing an extract derived from our human parthenogenetic stem cell technologies.
	Going Concern
	The Company continues in the development stage and as such has accumulated losses from inception and expects to incur additional losses in the near future. The Company needs to raise additional working capital. The timing and degree of any future capital requirements will depend on many factors. Currently, the Company’s burn rate is approximately $470,000 per month, excluding capital expenditures and patent costs averaging $57,000 per month. There can be no assurance that the Company will be successful in maintaining its normal operating cash flow, and that such cash flows will be sufficient to sustain the Company’s operations through the first quarter of 2014. Based on the above, there is substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements were prepared assuming that the Company is a going concern. The condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.
	Management’s plans in regard to these matters are focused on managing its cash flow, the proper timing of its capital expenditures, and raising additional capital or financing in the future. In the first quarter of 2013, to obtain funding for working capital purposes, the Company sold a total of 16,325,000 shares of common stock raising net proceeds of approximately $3.3 million. In July 2013, we closed a financing transaction contemplated by our S-1 Registration Statement on file with the U.S. Securities and Exchange Commission. We issued 20,000,000 Units in this transaction, raising net proceeds of approximately $2.4 million. Each Unit issued consists of a share of common stock and a Series A Warrant. Each purchaser also received a Series B Warrant for each Unit purchased. During the third quarter of 2013, the Company received net proceeds of $242,000 upon the exercise of 1,700,000 Series B Warrants for 1,700,000 additional Units. Subsequent to September 30, 2013, the Company received additional net proceeds of $2.1 million upon the exercise of 15,054,822 Series B Warrants for 15,054,822 additional Units, but prior to the expiration of the Series B Warrants on October 24, 2013. For further discussion regarding these transactions, see Note 6, Capital Stock and Note 11, Subsequent Events.
	Basis of Presentation
	International Stem Cell Corporation was formed in June 2006. BTHC III, Inc. was a shell company that had no operations and no net assets. For accounting purposes the acquisition has been treated as a recapitalization of BTHC III with ISC California as the accounting acquirer (reverse acquisition). The historical statements prior to June 2006 are those of Lifeline Cell Technology, LLC, the wholly-owned subsidiary of ISC California.
	The Company is a development-stage company with no revenue generated from its principal operations in therapeutic and biomedical products development through research and development efforts. To date, the Company has generated limited and unpredictable revenue to support its core therapeutic research and development efforts.
	The accompanying unaudited condensed consolidated financial statements included herein have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q.
	These financial statements do not include all information and notes required by generally accepted accounting principles for complete financial statements. However, except as disclosed herein, there has been no material change in the information disclosed in the notes to consolidated financial statements included in the annual report on Form 10-K of International Stem Cell Corporation and Subsidiaries for the year ended December 31, 2012. When used in these notes, the terms “Company,” “we,” “us,” or “our” mean International Stem Cell Corporation and all entities included in our unaudited condensed consolidated financial statements.
	In the opinion of management, the unaudited condensed consolidated financial information for the interim periods presented reflects all adjustments, consisting of only normal and recurring adjustments, necessary for a fair presentation of the Company’s consolidated results of operations, financial position and cash flows. The unaudited condensed consolidated financial statements and the related notes should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2012 included in the Company’s annual report on Form 10-K. Operating results for interim periods are not necessarily indicative of the operating results for any other interim period or an entire year.
	Principles of Consolidation
	The Company’s consolidated financial statements include the accounts of International Stem Cell Corporation and its subsidiaries after intercompany balances and transactions have been eliminated.
	The preparation of financial statements requires that management make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates.
	Cash Equivalents
	The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents.
	Restricted Cash
	The Company is required to maintain $50,000 in a restricted certificate of deposit account in order to fully collateralize a revolving credit card account.
	Inventories
	Inventories are accounted for using the first-in, first-out (FIFO) method for LSC products, and specific identification method for LCT products. Inventory balances are stated at the lower of cost or market. Laboratory supplies used in the research and development process are expensed as consumed. Inventory is reviewed periodically for product expiration and obsolescence and is adjusted accordingly.
	Accounts Receivable
	Trade accounts receivable are recorded at the net invoice value and are not interest bearing. Accounts receivable primarily consist of trade accounts receivable from the sales of LCT’s products, timing of cash receipts by the Company related to LSC credit card sales to customers, as well as LSC trade receivable amounts related to spa and distributor sales. The Company considers receivables past due based on the contractual payment terms. The Company reviews its exposure to accounts receivable and reserves specific amounts if collectability is no longer reasonably assured. As of September 30, 2013 and December 31, 2012, the Company had an allowance for doubtful accounts totaling $19,000 and $4,000, respectively.
	Property and Equipment
	Property and equipment are stated at cost. The provision for depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets, generally over five years. The costs of major remodeling and leasehold improvements are capitalized and amortized over the shorter of the remaining term of the lease or the life of the asset.
	Intangible Assets
	Intangible assets consist of acquired research and development rights used in research and development, and capitalized legal fees related to the acquisition, filing, maintenance, and defense of patents. Patent or patent license amortization only begins once a patent license is acquired or a patent is issued by the appropriate authoritative bodies. In the period in which a patent application is rejected or efforts to pursue the patent are abandoned, all the related accumulated costs are expensed. Patents and patent licenses are recorded at cost of $2,531,000 and $2,083,000 at September 30, 2013 and December 31, 2012, respectively, and are amortized on a straight-line basis over the shorter of the lives of the underlying patents or the useful life of the license. Amortization expense for the three months ended September 30, 2013 and 2012 amounted to $16,000 and $16,000, respectively, while amortization expense for the nine months ended September 30, 2013 and 2012 was $46,000 and $49,000, respectively. All amortization expense related to intangible assets is included in research and development expense. Accumulated amortization as of September 30, 2013 and December 31, 2012 was $495,000 and $449,000, respectively. Additional information regarding patents and patent licenses is included in Note 4.
	Long-lived Asset Impairment
	The Company reviews long-lived assets for impairment when events or changes in business conditions indicate that their carrying value may not be recovered, and at least annually. The Company considers assets to be impaired and writes them down to fair value if expected associated undiscounted cash flows are less than the carrying amounts. Fair value is the present value of the associated cash flows. The Company did not recognize material impairments on its long-lived assets during the three and nine months ended September 30, 2013 and 2012.
	Product Sales
	The Company recognizes revenue from product sales at the time of shipment to the customer, provided no significant obligations remain and collection of the receivable is reasonably assured. If the customer has a right of return, the Company recognizes product revenues upon shipment, provided that future returns can be reasonably estimated. In the case where returns cannot be reasonably estimated, revenue will be deferred until such estimates can be made or the right of return has expired. LSC’s revenue accounted for 49% and 48% of total revenue during the nine months ended September 30, 2013 and 2012, respectively. LCT contributed 51% and 52% of total revenue during the nine months ended September 30, 2013 and 2012, respectively.
	Deferred Revenue
	The Company recognizes revenue from LSC products when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the seller’s price to the buyer is fixed or determinable, and collectability is reasonably assured. However, LSC products sold through web-based channels have a 30-day right of return guarantee and therefore, the Company defers all revenue associated with these product sales until the 30-day guarantee has expired. In addition, all costs associated with these product sales are reclassified against the deferred revenue account so that the net deferred revenue balance is presented. At September 30, 2013 and December 31, 2012, net deferred revenue totaled $156,000 and $233,000, respectively.
	Cost of Sales
	Cost of sales consists primarily of salaries and benefits associated with employee efforts expended directly on the production of the Company’s products and include related direct materials, general laboratory supplies and allocation of overhead. Certain of the agreements under which the Company has licensed technology will require the payment of royalties based on the sale of its future products. Such royalties will be recorded as a component of cost of sales. Additionally, the amortization of license fees or milestone payments related to developed technologies used in the Company’s products will be classified as a component of cost of sales to the extent such payments become due in the future.
	Research and Development Costs
	Research and development costs, which are expensed as incurred, are primarily comprised of costs and expenses for salaries and benefits associated with research and development personnel, overhead and occupancy, contract services, and amortization of license costs for technology used in research and development with alternative future uses.
	Registration Payment Arrangements
	In accordance with applicable authoritative guidance, the Company is required to separately recognize and measure registration payment arrangements, whether issued as a separate agreement or included as a provision of a financial instrument or other agreement. Such payments include penalties for failure to effect a registration of securities.
	Fair Value Measurements
	On January 1, 2008, the Company adopted authoritative guidance for fair value measurements and fair value disclosures. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:
		Level 1	Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
		Level 2	Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability; and
		Level 3	Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).
	Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.
	The table below sets forth a summary of the fair values of the Company’s assets and liabilities as of September 30, 2013 (in thousands).
			Total			Level 1		Level 2		Level 3
	ASSETS:
	Cash equivalents		$	5		$	5	$	—	$	—
	LIABILITIES:
	Fair value of warrant liability		$	4,389		$	—	$	—	$	4,389
	The table below sets forth a summary of the fair values of the Company’s assets and liabilities as of December 31, 2012 (in thousands).
			Total			Level 1		Level 2		Level 3
	ASSETS:
	Cash equivalents		$	5		$	5	$	—	$	—
	The following table displays the rollforward activity of liabilities with inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity):
			Fair Value of Warrant Liability
	Beginning balance at December 31, 2011		$	38
	Issuances			—
	Adjustments to estimated fair value			(38	)
Ending balance at December 31, 2012			—
Issuances			4,635
Exercises			(219	)
Adjustments to estimated fair value			(27	)
Ending balance at September 30, 2013		$	4,389
Income Taxes
The Company accounts for income taxes in accordance with applicable authoritative guidance, which requires the Company to provide a net deferred tax asset/liability equal to the expected future tax benefit/expense of temporary reporting differences between book and tax accounting methods and any available operating loss or tax credit carryforwards.
Use of Estimates
The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements. Significant estimates include patent life (remaining legal life versus remaining useful life), inventory carrying values and transactions using the Black-Scholes option pricing model, e.g., warrants and stock options. Actual results could differ from those estimates.
Fair Value of Financial Instruments
The Company believes that the carrying value of its cash and cash equivalents, receivables, accounts payable and accrued liabilities as of September 30, 2013 and December 31, 2012 approximate their fair values because of the short-term nature of those instruments.
Income (Loss) Per Common Share
The computation of net loss per common share is based on the weighted average number of shares outstanding during each period. The computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the period plus the common stock equivalents, which would arise from the exercise of stock options and warrants outstanding using the treasury stock method and the average market price per share during the period. At September 30, 2013, there were 596,250 non-vested restricted shares, 67,395,832 shares issuable upon exercise of warrants, and 17,914,518 vested and 5,780,175 non-vested stock options outstanding; and at September 30, 2012, there were 335,000 non-vested restricted shares, 3,530,000 warrants, and 14,397,857 vested and 9,132,615 non-vested stock options outstanding. These restricted shares, options and warrants were not included in the diluted loss per share calculation because the effect would have been anti-dilutive.
Comprehensive Income
Comprehensive income or loss includes all changes in equity except those resulting from investments by owners and distributions to owners. The Company did not have any items of comprehensive income or loss other than net loss from operations for the three and nine months ended September 30, 2013 and 2012 or the period from inception through September 30, 2013.
Recent Accounting Pronouncements
There were no new accounting pronouncements during the nine months ended September 30, 2013, as compared to the recent accounting pronouncements described in the Annual Report on Form 10-K for the fiscal year ended December 31, 2012, that are of significance, or potential significance, to the Company.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2013
Inventory Disclosure [Abstract]	'
Inventory	'
	2. Inventory
	Inventories are accounted for using the first-in, first-out (FIFO) method for Lifeline Skin Care products, and specific identification method for Lifeline Cell Technology products. Lab supplies used in the research and development process are expensed as consumed. Inventory is reviewed periodically for product expiration and obsolete inventory and adjusted accordingly. The components of inventories are as follows (in thousands):
		September 30,			December 31,
		2013			2012
	Raw materials	$	141		$	276
	Work in process		428			211
	Finished goods		868			748
	Total		1,437			1,235
	Less: allowance for inventory obsolescence		(77	)		(36	)
	Inventory, net	$	1,360		$	1,199

Property_and_Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2013
Property Plant And Equipment [Abstract]	'
Property and Equipment	'
	3. Property and Equipment
	Property and equipment consists of the following (in thousands):
		September 30,			December 31,
		2013			2012
	Machinery and equipment	$	1,092		$	1,072
	Computer equipment		321			347
	Office equipment		225			225
	Leasehold improvements		839			830
			2,477			2,474
	Less: accumulated depreciation and amortization		(1,626	)		(1,340	)
	Property and equipment, net	$	851		$	1,134
	Depreciation expenses for the three and nine months ended September 30, 2013 were $100,000 and $301,000 respectively. During the same periods in the prior year, depreciation expenses were $106,000 and $320,000, respectively.

Patent_Licenses

Patent Licenses	9 Months Ended
	Sep. 30, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Patent Licenses	'
	4. Patent Licenses
	On December 31, 2003, LCT entered into an Option to License Intellectual Property agreement with Advanced Cell Technology, Inc. (“ACT”) for patent rights and paid ACT $340,000 in option and license fees. On February 13, 2004, LCT and ACT amended the Option agreement and LCT paid ACT additional option fees of $22,500 for fees related to registering ACT’s patents in selected international countries.
	On May 14, 2004, LCT amended the licensing agreement with ACT for the exclusive worldwide patent rights for the following ACT technologies: UMass IP, ACT IP and Infigen IP, which terms are summarized below. The additional license fees aggregate a total of $400,000 and were secured by separate convertible promissory notes. The notes bore no interest unless they were not repaid at maturity, in which event they shall thereafter bear interest at an annual rate equal to the lesser of 10% or the maximum non-usurious rate legally allowed.
	The notes could be converted at the option of ACT into the first equity financing of LCT with cash proceeds in excess of $5,000,000 under the following conditions: i) Upon the consummation of the First Equity Financing; or ii) Immediately prior to the closing of any merger, sale or other consolidation of the Company or of any sale of all or substantially all assets of the Company which occurs prior to the First Equity Financing (an “Acquisition Event”). Notwithstanding the above, and only in the event that a conversion resulting from such Acquisition Event would result in a security not traded on a national stock exchange (including NASDAQ and NASDAQ small cap), upon written notice to the Company not later than five days after the consummation of the Acquisition Event and notice of the Acquisition Event to the holder of the note, the holder may elect to receive payment in cash of the entire outstanding principal of this Note. On February 7, 2013, the Company and ACT entered into Amended and Restated License Agreements for the purpose of completely amending and restating the terms of the license agreements. Under the terms of the Amendment the Company acquired exclusive world-wide rights to all human therapeutic uses and cosmetic uses from ATC and Infigen’s early work on parthenogenic-derived embryonic stem cells, as well as certain rights to patents covering Single Blastomere technology. Pursuant to the Amendment all minimum R&D requirements and all milestone payments due to ACT under the Exclusive License Agreement have been eliminated. The Company will no longer pay any royalties under the ACT IP Agreement and Infigen IP Agreement, and its obligation to pay royalties that ranged from 6%-12% under the UMass IP Agreement has been reduced to 0.25% of the net sales of products using technology covered by the UMass IP Agreement.
	As of September 30, 2013, the total amount capitalized related to the acquired ACT licenses was $747,000, and $1,730,000 related to the other patent acquisition costs.
	At September 30, 2013, future amortization expense related to our intangible assets subject to amortization is expected to be as follows (in thousands):
		Amount
	2013 (remaining three months)	$	15
	2014		61
	2015		61
	2016		61
	2017		61
	Thereafter		1,724
	Total	$	1,983

Advances

Advances	9 Months Ended
	Sep. 30, 2013
Text Block [Abstract]	'
Advances	'
	5. Advances
	Advance
	On June 18, 2008, the Company entered into an agreement with BioTime, Inc. (“Bio Time”), where Bio Time will pay an advance of $250,000 to Lifeline Cell Technology, a wholly-owned subsidiary of International Stem Cell Corporation, to produce, make, and distribute Joint Products. The $250,000 advance will be paid down with the first $250,000 of net revenues that otherwise would be allocated to LCT under the agreement. As of September 30, 2013 no revenues were realized from this agreement.
		September 30,		December 31,
		2013		2012
	BioTime, Inc. (in thousands)	$	250	$	250

Capital_Stock

Capital Stock	9 Months Ended
	Sep. 30, 2013
Equity [Abstract]	'
Capital Stock	'
	6. Capital Stock
	As of December 31, 2006, the Company was authorized to issue 200,000,000 shares of common stock, $0.001 par value per share, and 20,000,000 shares of preferred stock, $0.001 par value per share. In May 2012, the Company amended its Certificate of Incorporation to increase the authorized number of shares of common stock to 300,000,000.
	In October 2006, the board of directors of BTHC III approved a stock split of 4.42 shares to 1. As a result of the split, the outstanding common stock of BTHC III increased from 500,000 to 2,209,993 shares. Pursuant to the Share Exchange Agreement, each share of International Stem Cell Corporation common stock was exchanged for one share of BTHC III common stock. All numbers in the financial statements and notes to the financial statements have been adjusted to reflect the stock split for all periods presented.
	On December 27, 2006, the Company’s Board of Directors and holders of a majority of the outstanding shares approved an increase in the authorized capital stock of the Company to 200,000,000 shares of common stock, $0.001 par value per share, and 20,000,000 shares of preferred stock, $0.001 par value per share.
	In December 2006, the Company issued 1,350,000 shares of common stock, 350,000 of such shares in consideration for legal consulting services relating to the reverse merger and 1,000,000 shares in consideration for a contract to provide investor relations services which commenced September 1, 2006 for a period of one year.
	In January and February 2007, ISC California completed the Brookstreet financing and issued 1,370,000 shares of common stock that was part of a private placement of securities by ISC California during the second half of 2006. The net proceeds from the sale finalized in 2007 were $1,157,000, net of cash fees and expenses. In connection with the final settlement in 2007, the selling agent for the private placement received 274,000 additional warrants, which entitled the holder thereof to purchase through February 2012 that number of shares of common stock for $1.00 each.
	Series A Preferred Stock
	On January 15, 2008, to raise funds, the Company entered into a subscription agreement with accredited investors for the sale of between 1,000,000 and 5,000,000 of Series A Preferred Stock (“Series A Preferred”). Series A Units consist of one share of Series A Preferred and two Warrants (“Series A Warrants”) to purchase common stock for each $1.00 invested. The Series A Preferred was convertible into shares of common stock at market price on the date of the first finance closing, but not to exceed $1 per share and the Series A Warrants are exercisable at $0.50 per share. The Series A Preferred has an anti-dilution clause whereby, if the Company issues $1 million or more of equity securities or securities convertible into equity at a price below the respective exercise prices of the Series A Preferred or the Series A Warrant, such conversion and exercise prices shall be adjusted downward to equal the price of the new securities. The Series A Preferred has priority on any sale or liquidation of the Company equal to the purchase price of the Series A Units, plus a liquidation premium of 6% per year. If the Company elects to declare a dividend in any year, it must first pay to the Series A Preferred a dividend of the amount of the dividend the Series A Preferred holder would receive if the shares were converted just prior to the dividend declaration.
	Each share of Series A Preferred has the same voting rights as the number of shares of common stock into which it would be convertible on the record date. On March 30, 2012, the holder of the remaining 500,000 shares of Series A Preferred Stock converted his shares to a total of 2,000,000 shares of common stock. In May 2012, the Company filed a Certificate of Elimination for the Series A Preferred Stock to remove the powers, designations, preferences, privileges and other rights of the Series A Preferred Stock.
	Series B Preferred Stock
	On May 12, 2008, to obtain funding for working capital, the Company entered into a series of subscription agreements with five accredited investors for the sale of a total of 400,000 Series B Units, each Series B Unit consisting of one share of Series B Preferred Stock (“Series B Preferred”) and two Series B Warrants (“Series B Warrants”) to purchase common stock for each $1.00 invested.
	The total purchase price received by the Company was $400,000. The Series B Preferred is convertible into shares of common stock at the initial conversion ratio of two shares of common stock for each share of Series B Preferred converted (which was established based on an initial conversion price of $0.50 per share), and the Series B Warrants were exercisable at $0.50 per share until five years from the issuance of the Series B Warrants. The Series B Warrants expired unexercised in July 2013. The Series B Preferred and Series B Warrants contained anti-dilution clauses whereby, (subject to the exceptions contained in those instruments) if the Company issues equity securities or securities convertible into equity at a price below the respective conversion price of the Series B Preferred or the exercise price of the Series B Warrant, such conversion and exercise prices shall be adjusted downward to equal the price of the new securities, which has been triggered and the new price of the warrants was set at $0.25. During the first quarter of 2013, the Company issued additional shares of common stock at $0.20 per share, triggering an adjustment in the conversion price of the Series B Preferred Stock to $0.20. As a result of the 2013 S-1 Registration Offering discussed below, the conversion price for the Series B Preferred was reduced to $0.15. The Series B Preferred has a priority (senior to the shares of common stock, but junior to the shares of Series A Preferred Stock) on any sale or liquidation of the Company equal to the purchase price of the Series B Units, plus a liquidation premium of 6% per year. If the Company elects to declare a dividend in any year, it must first pay to the Series B Preferred holder a dividend equal to the amount of the dividend the Series B Preferred holder would receive if the Series B Preferred were converted just prior to the dividend declaration. Each share of Series B Preferred has the same voting rights as the number of shares of common stock into which it would be convertible on the record date. As of September 30, 2013 and December 31, 2012, the Company had 300,000 shares of the Series B Preferred Stock issued and outstanding.
	Fair Value of Warrants Issued with Series A and B Preferred Stock
	In accordance with the applicable authoritative guidance, the Company allocated the proceeds of the Series A and B preferred stock according to the value of the convertible preferred stock and the warrants based on their relative fair values. Fair value of the warrants issued with the Series A and Series B were determined using the Black-Scholes valuation model using risk-free interest rates of 3% and 3.37%, volatility rates of 65.0% and 57.9%, term of five years, and exercise price of $0.50.
	In connection with the Series A and B rounds of financing, each investor received a warrant to purchase up to a number of shares of common stock for $1.00 per share. Subsequently, the exercise price for those warrants was adjusted down to $0.25 per share.
	In August 2008, in accordance with the anti-dilution provisions of the securities, the conversion rates and exercise price were reduced to $0.25. Estimated adjusted fair value of the warrants was determined using the Black-Scholes valuation model using a risk-free interest rate of 3%, volatility rate of 57.9%, term of five years, and exercise price of $0.25. For Series A and Series B, the beneficial conversion feature and warrants were adjusted to $553,000 and $193,000, and $308,000 and $110,000, respectively.
	During the second quarter of 2010, the holders of the warrants issued to the purchasers of Series A and B Preferred Stock signed a waiver to give up their rights to the anti-dilution provisions related to the warrants and the exercise price is now fixed at $0.25. The modification to the warrants resulted in a change in classification from a liability to equity and the warrants were revalued at the date of modification. The revaluation of the warrants resulted in a reduction in the warrant value of $5,276,000 which was recorded as a credit to income. The adjusted value of the warrants of $804,971 was reclassified to additional paid-in capital, thus eliminating any fair value of outstanding warrant liability as of June 30, 2010.
	Series C Preferred Stock
	On August 20, 2008, to obtain funding for working capital, the Company entered into a subscription agreement with an accredited investor (the “Series C Investor”) to sell for $3,000,000 up to 3,000,000 shares of Series C Preferred Stock (“Series C Preferred”) at a price of $1.00 per Series C Preferred share. The Series C Preferred will be convertible into shares of common stock at $0.25 per share. The Series C Preferred had an anti-dilution clause whereby, if the Company issues 250,000 shares or more of equity securities or securities convertible into equity at a price below the conversion price of the Series C Preferred, the conversion price of the Series C Preferred shall be adjusted downward to equal the price of the new securities. The Series C Preferred shall have priority over the common stock on any sale or liquidation of the Company equal to the purchase price of the Series C Preferred Stock, plus a liquidation premium of 6% per year, but such payment may be made only after payment in full of the liquidation preferences of the Series A and Series B Preferred Stock then outstanding. If the Company elects to declare a dividend in any year, it must first pay to the Series C Preferred a dividend in the amount of the dividend the Series C Preferred holder would receive if converted just prior to the dividend declaration. Each share of Series C Preferred shall have the same voting rights as the number of shares of common stock into which it would be convertible on the record date. 700,000 shares of Series C Preferred Stock were sold on August 20, 2008, and 1,300,000 shares of Series C Preferred Stock were sold on September 23, 2008. The beneficial conversion feature for the Series C preferred stock was $720,000. All the Series C Preferred Stock was issued to X-Master Inc., which is a related party and affiliated with our Chief Executive Officer and Co-Chairman of the Board of Directors Dr. Andrey Semechkin and Dr. Ruslan Semechkin, Chief Science Officer of International Stem Cell and a director. As of December 31, 2012, the Company had 2,000,000 shares of the Series C Preferred Stock issued and outstanding. On January 22, 2013, the holders of Series C Preferred Stock converted all of the outstanding shares of Series C Preferred Stock into common stock at $0.25 per share, or a total of 8,000,000 shares of common stock. On April 10, 2013, the Company filed a Certificate of Elimination for the Series C Preferred Stock. The Certificate of Elimination amended the provisions of the Certificate of Incorporation of the Company to eliminate the powers, designations, preferences, privileges and other rights of the Series C Preferred Stock.
	Series D Preferred Stock
	On December 30, 2008, to obtain funding for both working capital and the eventual repayment of the outstanding obligation under the OID Senior Secured Convertible Note with a principal amount of $1,000,000 issued in May 2008, the Company entered into a Series D Preferred Stock Purchase Agreement (the “Series D Agreement”) with accredited investors (the “Investors”) to sell for up to $5,000,000 up to 50 shares of Series D Preferred Stock (“Series D Preferred”) at a price of $100,000 per Series D Preferred share. The sale of the Series D Preferred closed on the following schedule: (1) 10 shares were sold on December 30, 2008; (2) 10 shares were sold on February 5, 2009; and (3) 10 shares were sold on each of March 20, 2009, and June 30, 2009 and 3 shares on September 30, 2009. The Company raised a total of $4,700,000 in the Series D Preferred Stock round. The beneficial conversion feature from the Series D Preferred Stock was recognized as a deemed dividend totaling $2,480,000. Of the Series D Preferred Stock issued, 10 shares of the Series D Preferred Stock was issued to X-Master Inc., which is a related party and affiliated with our Chief Executive Officer and Co-Chairman of the Board of Directors Dr. Andrey Semechkin and Dr. Ruslan Semechkin, Chief Science Officer of International Stem Cell and a director and 33 shares of the Series D Preferred Stock was issued to our Chief Executive Officer and Co-Chairman of the Board of Directors Dr. Andrey Semechkin. As of September 30, 2013 and December 31, 2012, we had 43 shares of the Series D Preferred Stock issued and outstanding. Historically, the Series D Preferred Stock earned cumulative dividends at a rate of 10% per annum through December 31, 2011 and 6% per annum effective January 1, 2012, payable 15 days after each quarter end. On October 12, 2012, the Company and the holders of all of the outstanding shares of Series D and Series G Preferred Stock entered into a Waiver Agreement (the “Waiver Agreement”) pursuant to which such holders irrevocably waived their right to receive any and all accrued but unpaid dividends and interest thereon on or after September 30, 2012 on the Series D and Series G Preferred Stock. Under the Waiver Agreement, the holders of Series D and Series G Preferred Stock are restricted from transferring any shares of Series D Preferred Stock unless the transferee agrees to be bound by the Waiver Agreement.
	On December 4, 2012, the holders of all of the outstanding shares of Series D Preferred Stock executed a Waiver of Anti-Dilution Rights (the “Anti-Dilution Waiver”) pursuant to which such holders waived all anti-dilution adjustment rights under the Certificate of Designation for the Series D Preferred Stock in connection with the offering of securities pursuant to the registration statement originally filed with the Securities and Exchange Commission on October 18, 2012, including the shares issuable on exercise of all warrants registered hereunder. The Anti-Dilution Waiver applied to the financing transaction that closed on July 24, 2013. The Anti-Dilution Waiver does not apply to any future issuances of securities which would otherwise trigger anti-dilution adjustments under the Certificate of Designation for the Series D Preferred Stock. During the first quarter of 2013, the Company issued additional shares of common stock at $0.20 per share, triggering an adjustment in the current conversion price of the Series D Preferred Stock to $0.20.
	During the three months ended September 30, 2013 and 2012, dividends of $0 and $64,000, respectively, were paid to the holders and for the nine months ended September 30, 2013 and 2012, dividends of $0 and $237,000, respectively, were paid to the holders. As of September 30, 2013 and December 31, 2012, no Series D Preferred Stock dividends were accrued.
	Series E Preferred Stock
	On June 30, 2009, the Company entered into a definitive agreement with Optimus Capital Partners, LLC (“Investor”) for a $5 million investment commitment. The transaction was structured whereby the Company could draw down funds as needed, but had no obligation to make draws or use these funds if not needed. As funds were drawn down, the Company issued Series E Preferred Stock (the “Preferred Stock”). The Preferred Stock was not convertible into common stock and could be redeemed by the Company after one year. Each issue of Preferred Stock was accompanied by the issuance of five-year warrants to purchase common stock at 100% of the closing price of the Company’s common stock on the day prior to the date the Company gave notice of its election to draw funds. The total exercise value of warrants issued equaled 135% of the drawdown amount. Dividends on the Preferred Stock were payable in additional shares of non-convertible Preferred Stock at the rate of 10% per annum. A commitment fee of $250,000, payable in shares of common stock, was made to the Investor. As part of the agreement, the Company filed a registration statement on July 31, 2009, which was declared effective on September 30, 2009. The investment was used to fund operations and working capital needs of the Company and expand its scientific research.
	On July 31, 2009, the Company filed a registration statement with the Securities and Exchange Commission as part of the Preferred Stock Purchase Agreement the Company signed on June 30, 2009, between International Stem Cell Corporation and Optimus Capital Partners. Per the agreement, the Company was required to use its best efforts to promptly file (but in no event later than 30 days after the Effective Date) and cause to become effective as soon as possible a Registration Statement for the sale of all common shares. Each Registration Statement was required to comply when it became effective, and, as amended or supplemented, at the time of any Tranche Notice Date, Tranche Closing Date, or issuance of any common shares, and at all times during which a prospectus was required by the Act to be delivered in connection with any sale of common shares, to comply, in all material respects, with the requirements of the Act. The Company is and has been in compliance with all applicable requirements of that agreement.
	To create the Series E Preferred sold to the Investor under the Agreement, on June 30, 2009, the Company amended its Certificate of Incorporation by filing a Certificate of Designation of Preferences, Rights and Limitations of the Series E Preferred. The Series E Preferred had priority over the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and common stock on the proceeds from any sale or liquidation of the Company in an amount equal to the purchase price of the Series E Preferred, plus any accrued but unpaid dividends. From the date of issuance of the Series E Preferred, dividends at the rate per annum of ten percent (10%) of the Purchase Price per share accrued on such shares of Series E Preferred. Following the first anniversary of the issuance date, the Company had the right at its option to redeem the Series E Preferred at an amount equal to the purchase price of the Series E Preferred, plus any accrued but unpaid dividends and plus a redemption premium that declines from 26% (for redemptions between the first and second anniversary of issuance) to zero (for redemptions after the fourth anniversary of issuance).
	During 2010, the Company drew $2.4 million of the private equity financing and issued 24 shares of the Series E Preferred Stock, as well as issued 3.7 million warrants which were immediately exercised to purchase 3.7 million shares of the Company’s common stock.
	Exchange Agreement Series E Preferred Stock
	On June 11, 2010, the Company entered into an Exchange Agreement (the “Optimus Exchange Agreement”) with Optimus Capital Partners, LLC (“Optimus”) under which the Company and Optimus agreed to exchange all of the Series E Preferred Stock previously issued to Optimus pursuant to the Preferred Stock Purchase Agreement dated June 30, 2009 (the “Optimus Preferred Stock Agreement”) for all of the promissory notes of Optimus (the “Optimus Notes”) issued to the Company in that transaction as payment for shares of the Company’s common stock. As part of the exchange transaction, the Company agreed to waive all accrued interest on the Optimus Notes and Optimus agreed to waive all accrued dividends and redemption premiums on the Series E Preferred Stock. The exchange was completed in June 2010 and is discussed in more detail below. Following the return of all shares of Series E Preferred Stock, the Company filed a Certificate of Elimination for the Series E Preferred Stock to remove the powers, preferences, privileges and other rights of the Series E Preferred Stock.
	Series F Preferred Stock
	On May 4, 2010, International Stem Cell Corporation entered into a Preferred Stock Purchase Agreement with Socius CG II, Ltd., a Bermuda exempted company (the “Investor”), to sell for up to $10,000,000 up to one thousand (1,000) shares of Series F Preferred Stock (“Series F Preferred”) at a price of $10,000 per Series F Preferred share. The Company was entitled to determine the time and amount of Series F Preferred to be purchased by the Investor, and the Company intended to sell all 1,000 shares of Series F Preferred at a single time. The Series F Preferred could not be converted into common stock and was redeemable by the Company. Under the terms of the Agreement, the Company provided the Investor with a non-refundable fee of 250,000 shares of Company common stock (the “Fee Shares”) and issued the Investor a warrant to purchase up to 7,000,000 shares of the Company’s common stock, with an exercise price of $1.93 per share, subject to adjustment. The closing of the sale of the Series F Preferred took place in early June 2010.
	Exchange Agreement Series F Preferred Stock
	On June 11, 2010, the Company, entered into an Exchange Agreement (the “Socius Exchange Agreement”) with Socius CG II, Ltd. (“Socius”) under which the Company and Socius agreed to exchange all of the Series F Preferred Stock previously issued to Socius pursuant to the Preferred Stock Purchase Agreement dated May 4, 2010 (the “Socius Preferred Stock Agreement”) for all of the promissory notes of Socius (the “Socius Notes”) issued to the Company in that transaction as payment for shares of the Company’s common stock and a $2.5 million note issued in partial payment for the Socius Series F Preferred Stock. As part of the exchange transaction, the Company agreed to waive all accrued interest on the Socius Notes and Socius agreed to waive all accrued dividends and redemption premiums on the Socius Series F Preferred Stock. The exchange was completed in June 2010 and is discussed in more detail below. Following the return of all shares of Series F Preferred Stock, the Company filed a Certificate of Elimination for the Series F Preferred Stock to remove the powers, preferences, privileges and other rights of the Series F Preferred Stock.
	Perpetual Preferred Stock
	As part of the Series E financing agreement, the Company recorded a Perpetual Preferred Stock equal to the amount of financing received during the year, plus accrued dividends, and Note Receivable equal to 135% of financing received, which represents the amount of warrant coverage per the agreement, plus accrued interest. In accordance with applicable authoritative guidance on Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, the Company classified the Note Receivable as contra Equity (“Note subscription on Perpetual Preferred Stock”) and the Perpetual Preferred Stock as a liability (“Long Term Perpetual Preferred Stock”). The Note Receivable accrued interest at a rate of 2% per year and the Perpetual Preferred Stock accrued a 10% dividend per year. The Company allocated the proceeds of the Series E Preferred Stock according to the value of the preferred stock and the fair value of the warrants. The estimated adjusted fair values of the warrants were determined using the Black-Scholes valuation model with risk-free interest rates ranging from 2.40% to 2.65%, volatility rates ranging from 64.46% to 65.33%, term of five years, and exercise prices ranging from $0.56 to $0.74.
	As a result of the exchange transactions for the Series E and Series F Preferred stock, all of the Company’s obligations under the previously outstanding Series E Preferred Stock and Series F Preferred Stock, which collectively had liquidation preferences of $15 million senior to the shares of the Company’s common stock and redemption premiums that started at 26% of the liquidation preference, were retired and the Company no longer held any promissory notes of either Socius or Optimus. Because the parties to these exchange transactions determined that the instruments and rights being exchanged were of equivalent value, neither party paid any cash to the other party in the exchange transaction. Therefore, as of June 30, 2010, the Company reversed out all of the Perpetual Preferred Stock and the Notes Receivable related to the Perpetual Preferred Stock.
	Series G Preferred Stock
	On March 9, 2012, the Company entered into a Series G Preferred Stock Purchase Agreement (the “Series G Agreement”) with AR Partners, LLC (the “Purchaser”) to sell five million (5,000,000) shares of Series G Preferred Stock (“Series G Preferred”) at a price of $1.00 per Series G Preferred share, for a total purchase price of $5,000,000. The Purchaser is an affiliate of Dr. Andrey Semechkin, the Company’s Co-Chairman and Chief Executive Officer, and Dr. Ruslan Semechkin, Chief Science Officer of International Stem Cell and a director.
	The Series G Preferred was convertible into shares of common stock at $0.40 per share, resulting in an initial conversion ratio of 2.5 shares of common stock for every share of Series G Preferred. The conversion price may be adjusted for stock splits and other combinations, dividends and distributions, recapitalizations and reclassifications, exchanges or substitutions and is subject to a weighted average adjustment in the event of the issuance of additional shares of common stock below the conversion price. The Series G Preferred shares have priority over the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and common stock on the proceeds from any sale or liquidation of the Company in an amount equal to the purchase price of the Series G Preferred, plus any accrued but unpaid dividends, but such payment may be made only after payment in full of the liquidation preferences payable to holders of any shares of Series D Preferred Stock then outstanding. Historically, from the date of issuance of the Series G Preferred, dividends at the rate per annum of six percent (6%) of the Purchase Price per share accrued quarterly on such shares of Series G Preferred. Each share of Series G Preferred has the same voting rights as the number of shares of common stock into which it would be convertible on the record date. As long as there are at least 1,000,000 shares of Series G Preferred outstanding, the holders of Series G Preferred have (i) the initial right to propose the nomination of two members of the Board, at least one of which nominees shall be subject to the approval of the Company’s independent directors, for election by the stockholders at the Company’s next annual meeting of stockholders, or, elected by the full board of directors to fill a vacancy, as the case may be, and (ii) the right to approve any amendment to the certificate of incorporation, certificates of designation or bylaws, in manner adverse to the Series G Preferred, alter the percentage of board seats held by the Series G directors or increase the authorized number of shares of Series G Preferred. At least one of the two directors nominated by holders of the Series G Preferred shares shall be independent based on the NASDAQ listing requirements. On October 12, 2012, the Company and the holders of all of the outstanding shares of Series D and Series G Preferred Stock entered into the Waiver Agreement pursuant to which such holders irrevocably waived their right to receive any and all accrued but unpaid dividends and interest thereon on or after September 30, 2012 on the Series D and Series G Preferred Stock. Accordingly, dividends from inception in the amount of $93,000 accreted to the carrying value of Series G preferred stock have been reversed. Under the Waiver Agreement, the holders of Series D and Series G Preferred Stock are restricted from transferring any shares of Series D Preferred Stock or Series G Preferred Stock unless the transferee agrees to be bound by the Waiver Agreement. No dividends were paid to the holders during the nine months ended September 30, 2013 and 2012. As of September 30, 2013 and December 31, 2012, no Series G Preferred Stock dividends were accrued.
	The Company determined that the Series G convertible preferred shares have a contingent redemption feature allowing redemption by the holder under only some very limited circumstances (“deemed liquidation events”). As the event that may trigger the redemption of the convertible preferred stock is not solely within the Company’s control, the convertible preferred stock has been classified as mezzanine equity (outside of permanent equity) on the Company’s condensed consolidated balance sheet. Additionally, legal costs related to the Series G financing in the amount of $59,000 were recorded in the mezzanine equity as well.
	The Company determined that as the initial conversion price at the date of close of the Series G transaction was lower than the closing market price on that day (March 9, 2012), a beneficial conversion feature existed in the amount of $1,375,000. Such amount was recorded as a discount on the Series G convertible preferred stock with a corresponding increase in additional paid-in capital. Based on the appropriate accounting guidance, the Company is required to recognize the discount over the period of time from the issuance of preferred shares until the convertible preferred shares can be first converted. As the Series G convertible shares are convertible immediately following their issuance, the discount amount of $1,375,000 was recognized in March 2012 as a deemed dividend with a corresponding increase in accumulated deficit. During the first quarter of 2013, the Company issued additional shares of common stock at $0.20 per share, triggering an adjustment in the conversion price of the Series G Preferred Stock at $0.37, and the conversion ratio to 2.67 shares of common stock for every share of Series G Preferred. As a result of the 2013 S-1 Registration Offering during the third quarter of 2013, the conversion price and the conversion ratio for the Series G Preferred were adjusted to $0.30 and 3.28, respectively.
	Common Stock Purchase Agreement
	On December 9, 2010, International Stem Cell Corporation (“ISCO” or the “Company”) entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) with Aspire Capital Fund, LLC (“Aspire Capital”) which provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $25.0 million of shares of ISCO common stock (the “Purchase Shares”) over the term of the Purchase Agreement. In connection with the execution of the Purchase Agreement, ISCO sold Aspire 333,333 shares of common stock for a total of $500,000. Under the Purchase Agreement, the Company also agreed to pay Aspire Capital a commitment fee of 500,000 shares of its common stock. The Company is not obligated to pay any additional expense reimbursement or any placement agent fees in connection with the transaction.
	The Purchase Agreement is intended to provide the Company with a source of capital of up to $25 million over a term of up to three years. The sales price of any shares the Company elects to sell will be known by the Company at the time it makes the decision to sell and will be determined by a formula (described below) based on the price of the Company’s stock over the preceding 12 days. As a result, the Company will be able to sell shares on whatever schedule it believes best suits its needs and is not required to sell any shares unless it deems such sales to be beneficial to the Company.
	Once the Registration Statement (referred to below) is effective, on any day on which the principal market for shares of ISCO common stock is open for trading, over the three-year term of the Purchase Agreement, the Company has the right, in its sole discretion, to provide Aspire Capital with a purchase notice (each, a “Purchase Notice”) directing Aspire Capital to purchase the number of shares of ISCO common stock specified in the Purchase Notice. The number of shares the Company may designate in the Purchase Notice varies based on the closing price of the ISCO common stock on the date of the Purchase Notice. The Company may direct Aspire Capital to purchase up to: (1) 100,000 shares of common stock so long as the closing price is above $0.25; (2) 150,000 shares of common stock so long as the closing price is above $1.25; (3) 200,000 shares of common stock so long as the closing price is above $1.75 and (4) 300,000 shares of common stock so long as the closing price is above $2.25. The purchase price per share (the “Purchase Price”) for each Purchase Notice is the lower of (i) the lowest sale price for the common stock on the date of sale or (ii) the arithmetic average of the three lowest closing sale prices for the common stock during the 12 consecutive business days ending on the business day immediately preceding the purchase date of those securities.
	The timing and the number of shares covered by each Purchase Notice are determined in the Company’s sole discretion, and the applicable Purchase Price will be determined prior to delivery of any Purchase Notice. The Company may deliver multiple Purchase Notices to Aspire Capital from time to time during the term of the Purchase Agreement, so long as the most recent purchase has been completed. There are no trading volume requirements or restrictions under the Purchase Agreement. Aspire Capital has no right to require any sales by the Company, but is obligated to make purchases as directed in accordance with the Purchase Agreement. The Purchase Agreement contains customary representations, warranties, covenants, closing conditions and indemnification and termination provisions. The Purchase Agreement may be terminated by the Company at any time, at its discretion, without any cost or penalty. Aspire Capital has agreed not to cause, or engage in any manner whatsoever, any direct or indirect short selling or hedging of ISCO common stock. The Company did not pay any additional amounts to reimburse or otherwise compensate Aspire Capital in connection with the transaction. There are no limitations on use of proceeds, financial or business covenants, restrictions on future funding, rights of first refusal, participation rights, penalties or liquidated damages in the Purchase Agreement.
	The Company’s net proceeds will depend on the Purchase Price and volume and frequency of the Company’s sales of shares to Aspire Capital; provided, however, that the maximum aggregate proceeds from sales of shares to Aspire Capital under the Purchase Agreement is $25 million. The Company anticipates that delivery of Purchase Notices will be made subject to market conditions, in light of the Company’s capital needs from time to time and under the limitations contained in the Purchase Agreement. The Company expects to use proceeds from sales of shares to Aspire Capital for funding its research and development activities and for general corporate purposes and working capital requirements.
	Registration Rights
	In connection with the Purchase Agreement, the Company also entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with Aspire Capital, dated December 9, 2010. The Registration Rights Agreement provides, among other things, that the Company will register the resale of the commitment fee shares and the shares that have been or may be sold to Aspire Capital (collectively, the “Securities”) by Aspire Capital. The Company further agreed to keep the Registration Statement effective and to indemnify Aspire Capital for certain liabilities in connection with the sale of the Securities under the terms of the Registration Rights Agreement.
	During the three and nine months ended September 30, 2013 and 2012, the Company has issued 0, 1,200,000, 0 and 5,000,000 shares of common stock, respectively, to Aspire Capital, raising $0, $264,000, $0 and $2.1 million, respectively, which was used to fund its operational activities.
	2013 Securities Purchase Agreements for Common Stock
	On January 22, 2013, to obtain funding for working capital purposes, the Company entered into a Securities Purchase Agreement (the “January 2013 Purchase Agreement”) with Dr. Andrey Semechkin and Dr. Simon Craw to sell a total of 10,125,000 shares of common stock at a price of $0.20 per share, for a total purchase price of $2,025,000. Dr. Andrey Semechkin is the Company’s Co-Chairman and Chief Executive Officer. Dr. Simon Craw is the Company’s Executive Vice President Business Development. The sale of the shares of common stock was completed on January 22, 2013. In connection with the sale of these shares the Company issued to each purchaser a warrant, exercisable for a period of 5 years, to purchase (at an exercise price of $0.20 per share) a number of shares of common stock equal to 50% of the shares purchased by that purchaser, for a total of 5,062,500 shares subject to the warrants.
	On March 12, 2013, to obtain funding for working capital purposes, the Company entered into a Securities Purchase Agreement (the “March 2013 Purchase Agreement”) with certain investors, including Dr. Andrey Semechkin, to sell a total of 5,000,000 shares of common stock at a price of $0.20 per share, for a total purchase price of $1,000,000. Dr. Andrey Semechkin is the Company’s Co-Chairman and Chief Executive Officer and purchased $100,000 worth of common stock. Each of the other investors has had a long-standing relationship with the Company and has closely followed the Company. The sale of the shares of common stock was completed on March 12, 2013. In connection with the sale of these shares the Company issued to each investor a warrant, exercisable for a period of five years, to purchase (at an exercise price of $0.20 per share) a number of shares of common stock equal to 50% of the shares purchased by that investor, for a total of 2,500,000 shares subject to the warrants.
	2013 S-1 Registration Offering
	On July 19, 2013, to obtain funding for working capital purposes, the Company entered into subscription agreements with certain investors (the “Investors”) relating to the sale by the Company of (i) 20,000,000 units (each a “Unit”, and collectively, the “Units”), with each Unit consisting of (x) one share of common stock, par value $0.001 per share, and (y) one Series A Warrant to purchase one share of the Company’s common stock at an exercise price of $0.15 per share and (ii) 20,000,000 Series B Warrants, each to purchase one Unit, for aggregate gross proceeds of $3,000,000, before placement agent fees and other estimated offering expenses and fees (the “Offering”). The Units were not issued or certificated. The Investors received only shares of common stock, Series A Warrants and Series B Warrants. The common stock, the Series A Warrants and the Series B Warrants were and may be transferred separately immediately after their issuance. The Investors in the Offering received one Series B Warrant for each Unit purchased by them in the Offering. Dr. Andrey Semechkin, the Company’s Co-Chairman and Chief Executive Officer, purchased 5,998,999 Units and 5,998,999 Series B Warrants in the Offering and Ruslan Semechkin, the Company’s Chief Science Officer, purchased 667,667 Units and 667,667 Series B Warrants in the offering for an aggregate price of $1,000,000.
	On July 19, 2013, the Company also entered into a placement agent agreement (the “Placement Agent Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”), pursuant to which the Placement Agent agreed to act on a reasonable best efforts basis for the Offering. The Company paid the Placement Agent a cash fee equal to 5% of the gross proceeds from the Offering and reimbursed the Placement Agent for its reasonable out-of-pocket expenses of $75,000. The Company also issued 666,666 Placement Agent Warrants to purchase Units equal to 5% of the aggregate number of Units issued in the Offering (other than the Units issued to Andrey Semechkin and Ruslan Semechkin). The Placement Agent Warrants have substantially the same terms as the Series B Warrants, except that the Placement Agent Warrants (i) have an exercise price of $0.15 per Unit, subject to adjustments similar to those applicable to the Series A Warrants, (ii) have a term of five years, (iii) provide for a cashless exercise, and (iv) otherwise comply with the requirements of the Financial Institutions Regulatory Authority, Inc. (FINRA). The Company also agreed to pay the Placement Agent a cash solicitation fee equal to 5% of the gross proceeds received by the Company upon the exercise of the Series B Warrants under certain circumstances.
	The Series A Warrants were immediately exercisable at an initial exercise price of $0.15 per share and will expire on the fifth anniversary of the initial date of issuance. The Series A Warrants were issued separately from the common stock included in the Units, and may be transferred separately immediately thereafter. Upon full exercise of the Series B Warrants, the Company could issue additional Series A Warrants to purchase up to an aggregate of 20,000,000 shares of the Company’s common stock. All Series A Warrants have the same expiration date. See Note 8, Stock Options and Warrants, Warrants Issued with Common Stock for detailed discussion of the anti-dilution provisions of the Series A Warrants and the price adjustment provisions of the Series B Warrants.
	The Series B Warrants were immediately exercisable at an initial exercise price of $0.15, subject to adjustment and expire on October 24, 2013. See Note 11, Subsequent Events for further information regarding the conclusion of the Series B Warrant transactions from October 1, 2013 to the expiration date of October 24, 2013.
	The net proceeds to the Company from the Offering, after deducting placement agent fees and cash offering expenses borne by the Company, and excluding any proceeds, from the exercise of the warrants issued in the offering, was approximately $2.4 million. The Offering closed on July 24, 2013.
	During the quarter ended September 30, 2013, 1,700,000 Series B Warrants were exercised for 1,700,000 additional Units for net proceeds of $242,000. The total additional Units consisted of 1,700,000 shares of common stock and 1,700,000 Series A Warrants.
	We account for our warrants in accordance with current accounting guidance, which defines how freestanding contracts that are indexed to and potentially settled in a Company’s own stock should be measured and classified. The authoritative accounting guidance prescribes that only warrants issued under contracts that cannot be net-cash settled and are both indexed to and settled in the Company’s common stock can be classified as equity. As the Series A and B Warrant agreements did not meet the specific conditions for equity classification, we are required to classify the fair value of the warrants issued as a liability, with subsequent changes in fair value to be recorded as income (loss) in the statement of operations upon revaluation of the fair value of warrant liability at each reporting period. Valuation of the Warrants was estimated at issuance on July 24, 2013, at the various warrant exercise dates, and at September 30, 2013 using the Monte-Carlo simulation model. The fair value is affected by changes in inputs to the model. The following assumptions were used as inputs to the model at September 30, 2013: stock price of $0.15 and warrant exercise price of $0.15 as of the valuation date; the Company’s historical stock price volatility of 87.7%; risk free interest rate on U.S. treasury notes of 1.33% for Series A Warrants, and .03% for Series B Warrants; a zero dividend rate; warrant expiration of 5 years for Series A and 0.07 years for the Series B Warrants; simulated as a daily interval and anti-dilution impact if the Company had to raise capital below $0.15 per share.
	The fair value of the warrant liability at the issuance date exceeded the gross proceeds received for the common shares, Series A Warrants and the Series B Warrants by $1.39 million. The Series A Warrants, Series B Warrants, and Placement Agent Warrants had fair values of $1.72 million, $2.65 million and $115,000 at issuance, respectively. The classification and valuation of the warrants resulted in total warrant liability of $4.5 million and $4.4 million as of the issuance date of July 24, 2013 and the revaluation date of September 30, 2013, respectively. During the three and nine months ended September 30, 2013, we recorded income of $27,000, in our consolidated condensed statements of operations related to the change in fair value of the warrant liability due to the revaluation at September 30, 2013 and the change in fair value of the Series B Warrants at each exercise date. As a result of the fair value of the warrant liability at issuance exceeding the total gross proceeds received, the transaction financing costs of $738,000 were recognized as additional other expense resulting in a net effect to other expense of $2.1 million for the three months ended September 30, 2013.
Reserved Shares
At September 30, 2013, the Company had shares of common stock reserved for future issuance as follows:
Options outstanding	23,694,693
Options available for future grant	16,032,480
Convertible preferred stock	39,899,151
Warrants	67,395,832
	147,022,156

Related_Party_Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	7. Related Party Transactions
	Other than with respect to the purchases of Series C, Series D, Series G Preferred Stock, 2013 Securities Purchase Agreements and the 2013 S-1 Registration offering discussed in Note 6 Capital Stock, the Company’s related party transactions were for related party dividends and for a facility lease.
	Dividend amounts related to Series D and Series G financing, were $0 at September 30, 2012. The Series D dividends were payable to both X-Master, Inc. and our Chief Executive Officer and Co-Chairman of the Board of Directors, Dr. Andrey Semechkin, while Series G Preferred Stock dividends were initially cumulative and payable upon conversion of the Series G shares or upon certain Series G deemed liquidation events to AR Partners, LLC. These amounts were paid during 2012. On October 12, 2012, the Company and the holders of all of the outstanding shares of Series D and Series G Preferred Stock entered into the Waiver Agreement pursuant to which such holders irrevocably waived their right to receive any and all accrued but unpaid dividends and interest thereon on or after September 30, 2012 on the Series D and Series G Preferred Stock. Accordingly, the Company reversed all previously accrued and unpaid dividends related to Series G Preferred Stock totaling $93,000. Under the Waiver Agreement, the holders of Series D and Series G Preferred Stock are restricted from transferring any shares of Series D Preferred Stock unless the transferee agrees to be bound by the Waiver Agreement. Pursuant to the Waiver Agreement, no dividends were accrued or paid during the three or nine months ended September 30, 2013.
	During the first quarter of 2011, the Company executed an operating lease for our corporate offices with S Real Estate Holdings LLC. S Real Estate Holdings LLC which is owned by Dr. Ruslan Semechkin, the Company’s Chief Science Officer and was previously owned by Dr. Andrey Semechkin, the Company’s Chief Executive Officer and Co-Chairman of the Board of Directors. The lease agreement was negotiated at arm’s length and was reviewed by the Company’s outside legal counsel. The terms of the lease were reviewed by a committee of independent directors, and the Company believes that, in total, those terms are at least as favorable to the Company as could be obtained for comparable facilities from an unaffiliated party. For the three months ended September 30, 2013 and 2012, the Company recorded $39,000 and $29,000, respectively, in rent and common area maintenance expenses that were related to the facility lease arrangement with related parties. Additionally, during the nine months ended September 30, 2013 and 2012, the Company recorded $118,000 and $86,000, respectively, related to the same arrangement with the related party.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	8. Income Taxes
	The Company estimated Federal and state tax losses for the current year and recorded a full valuation allowance against all net deferred tax assets. As such, no income tax provision has been recorded for the current period. The Company may be subject to IRC code section 382 which could limit the amount of the net operating loss and tax credit carryovers that can be used in future years. There can be no assurances that the Company will ever be able to realize the benefit of some or all of the loss and credit carryforwards either due to ongoing operating losses or due to ownership change limitations.

Stock_Options_and_Warrants

Stock Options and Warrants	9 Months Ended
	Sep. 30, 2013
Text Block [Abstract]	'
Stock Options and Warrants	'
	9. Stock Options and Warrants
	Stock Options
	The Company has adopted the 2006 Equity Participation Plan (the “2006 Plan”). The options granted under the 2006 Plan may be either qualified or non-qualified options. Up to 15,000,000 options may be granted to employees, directors and consultants under this Plan. Options may be granted with different vesting terms and expire no later than 10 years from the date of grant.
	In April 2010, the Company adopted the 2010 Equity Participation Plan (the “2010 Plan”). The options granted under the 2010 Plan may be either qualified or non-qualified options. Up to 18,000,000 options may be granted to employees, directors and consultants under the 2010 Plan. Options may be granted with different vesting terms and expire no later than 10 years from the date of grant.
	In November and December of 2009, the Company issued outside the 2006 and 2010 option plans non-qualified stock options to purchase 10,257,593 shares of common stock to certain employees and consultants. These options vest over 50 months and expire no later than 10 years from the date of grant.
	In accordance with applicable authoritative guidance, the Company is required to establish assumptions and estimates of the weighted-average fair value of stock options granted, as well as using a valuation model to calculate the fair value of stock-based awards. The Company uses the Black-Scholes option-pricing model to determine the fair-value of stock-based awards. All options are amortized over the requisite service periods. During the three months ended September 30, 2013 and 2012 and the nine months ended September 30, 2013 and 2012, the Company recognized $442,000, $534,000, $1.3 million and $1.8 million, as stock-based compensation expense, respectively. Unrecognized compensation expense related to stock options as of September 30, 2013 and 2012 was $2.3 million and $4.4 million, respectively, which is expected to be recognized over a weighted average period of approximately 1.7 years and 2.4 years, respectively.
	Stock-based compensation for stock options granted to non-employees has been determined using the estimated fair value of the stock options issued, based on the Black-Scholes Option Pricing Model. These options are revalued at each reporting period until fully vested, with any change in fair value recognized in the consolidated statements of operations.
	The fair value of options granted is estimated at the date of grant using a Black-Scholes option-pricing model with the following weighted-average assumptions for the three and nine months ended September 30, 2013 and 2012:
		Three Months			Nine Months			Three Months			Nine Months
		Ended			Ended			Ended			Ended
		September 30,			September 30,			September 30,			September 30,
		2013			2013			2012			2012
	Significant assumptions (weighted-average):
	Risk-free interest rate at grant date		0	%		0.95	%		0.88	%		0.94	%
	Expected stock price volatility		0	%		118.34	%		124.93	%		123.63	%
	Expected dividend payout		0	%		0	%		0	%		0	%
	Expected option life-years based on management’s estimate		0.0 yrs			6.1 yrs			5.6 yrs			5.7 yrs
	The following table summarizes options outstanding as of September 30, 2013:
	Options Outstanding										Options Exercisable and vested
	Exercise Prices	Number Outstanding			Weighted			Weighted Average			Number			Weighted Average		Weighted Average
					Average			Exercise Price			Exercisable			Remaining		Exercise Price
					Remaining									Contractual Life
					Contractual Life									(Years)
					(Years)
	$0.22-$0.50		5,198,300			7.31		$	0.37			2,612,100			5.56	$	0.42
	$0.51-$0.75		9,265,293			6.18		$	0.62			8,363,918			6.15	$	0.62
	$0.76-$1.00		1,895,000			3.77		$	0.98			1,791,000			3.52	$	0.99
	$1.01-$1.25		335,000			7.59		$	1.1			253,600			7.59	$	1.1
	$1.26-$1.50		1,171,100			6.37		$	1.31			926,700			6.24	$	1.32
	$1.51-$3.20		5,830,000			7.08		$	1.94			3,967,200			7	$	1.95
			23,694,693			6.49		$	0.96			17,914,518			6.02	$	0.96
	Transactions involving stock options issued to employees, directors and consultants under the 2006 Plan, the 2010 Plan and outside the plans are summarized below. Options issued have a maximum life of 10 years. The following table summarizes the changes in options outstanding and the related exercise prices for the Company’s common stock options issued:
		Number of			Weighted
		Shares issued			Average Exercise
		under			Price Per
		2006 Plan and			Share
		2010 Plan
	Outstanding at December 31, 2011		14,730,207		$	1.26
	Granted		2,398,000		$	0.38
	Exercised		(17,500	)	$	0.22
	Canceled or expired		(1,987,807	)	$	0.78
	Outstanding at December 31, 2012		15,122,900		$	1.18
	Granted		1,352,500		$	0.27
	Exercised		—		$	—
	Canceled or expired		(390,000	)	$	0.56
	Outstanding at September 30, 2013		16,085,400		$	1.12
		Number of			Weighted
		Shares issued			Average Exercise
		outside			Price Per
		the Plan			Share
	Outstanding at December 31, 2011		8,254,232		$	0.65
	Granted		—		$	—
	Exercised		—		$	—
	Canceled or expired		—		$	—
	Outstanding at December 31, 2012		8,254,232		$	0.65
	Granted		—		$	—
	Exercised		—		$	—
	Canceled or expired		(644,939	)	$	1
	Outstanding at September 30, 2013		7,609,293		$	0.62
	Warrants
	Brookstreet Securities Corporation
	As of December 31, 2006, Brookstreet Securities Corporation (“Brookstreet”) had earned 1,976,190 warrants as partial compensation for its services as placement agent for the raising of equity capital. An additional 274,000 warrants were earned by Brookstreet in the first quarter of 2007, for a total of 2,250,190 warrants related to the Company’s private placement. In addition, 426,767 warrants were granted to a number of individuals as compensation for services rendered to the Company. Each Warrant entitles the holder thereof to purchase the number of shares of common stock that could be purchased by the dollar amount of the Warrant being exercised at $1.00 in the case of the Brookstreet warrants and $0.80 in the case of the individuals’ warrants. The Company recognized the value attributable to the individuals’ warrants in the amount of $222,000 and applied it to general and administrative expense. The Company recognized the value attributable to the Brookstreet warrants in the amount of $1.2 million. The Company recognized the Brookstreet warrants as a component of additional paid-in capital with a corresponding reduction in additional paid-in capital to reflect this as a non-cash cost of the offering. Proceeds from the private equity placement totaled $9.9 million and are offset by cash offering costs of $1.5 million as well as the non-cash offering cost of $1.2 million related to the fair value of the Brookstreet warrants. The Company valued the Brookstreet warrants and the warrants issued to the individuals using the Black-Scholes pricing model and the following assumptions: contractual terms of 5 years and 3 years, average risk free interest rates of 4.58% and 5.13%, a dividend yield of 0% and 0%, and volatility of 71% and 63%, respectively.
	The number of warrants converted into common stock by Brookstreet was 484,675 for the completion of the Brookstreet financing and issued 1,370,000 shares of common stock that was part of a private placement of securities by ISC California during the second half of 2006. The net proceeds from the shares whose sale was finalized in 2007 was $1.2 million net of cash fees and expenses. In connection with the final settlement in 2007, the selling agent for the private placement received 274,000 additional warrants, which entitle the holder thereof to purchase that number of shares of common stock for $1.00 each.
During 2008, the Company raised additional capital by issuing Preferred Series A, B, C and D stock. This issuance of the Preferred Series C triggered an anti-dilutive clause in the Brookstreet warrant agreement, where Brookstreet would receive an adjustment downward in the price it pays for converting its warrants, which resulted in a deemed dividend of $337,000. Brookstreet earned a total of 2,250,190 warrants in 2006 and 2007 in connection with the Company’s private placement. Each Warrant entitles the holder thereof to purchase one share of common stock for $1.00, revalued to $0.56 per warrant. The Company recognized the value attributable to the warrants in the amount of $1.2 million in 2006 and $169,000 in 2007 as a component of additional paid-in capital with a corresponding reduction in additional paid-in capital to reflect the issuance as a non-cash cost of the offering. Prior to 2009, the Company valued the Brookstreet warrants using the Black-Scholes pricing model and the following assumptions: contractual terms of 5 years, an average risk free interest rate of 4.58%, a dividend yield of 0%, and volatility of 70.57%. During 2009, the Company issued a total of 3,510,206 shares of common stock which related to warrants originally issued to Brookstreet. Brookstreet converted a total of 612,267 warrants into 484,675 shares of common stock at an average cashless conversion price of $0.56 per share.
Implementation of Accounting Standards Code (ASC) 815-40-15, (formerly known as EITF 07-5 “Determining Whether an Instrument (or Embedded Feature) is Indexed to an Entity’s Own Stock Price”)
The Accounting Standards Code (ASC) 815-40-15, with an effective date of December 15, 2008, should have been implemented as of January 1, 2009, and in future periods. This Issue applies to any freestanding financial instrument or embedded feature that has all the characteristics of a derivative as described in ASC 815-10-15-83, (previously paragraphs 6–9 of Statement 133) for purposes of determining whether that instrument or embedded feature qualifies for the first part of the scope exception in ASC 815-10-74 (previously paragraph 11(a) of Statement 133). This Issue also applies to any freestanding financial instrument that is potentially settled in an entity’s own stock, regardless of whether the instrument has all the characteristics of a derivative for purposes of determining whether the instrument is within the scope of ASC 815-40.
During 2008, the Company issued a Series C Preferred round of financing which triggered the anti-dilution clause in the Brookstreet warrant agreement (“Brookstreet Warrants”). From issuing the Series C Preferred Stock, the exercise prices of the Brookstreet Warrants were revalued down to $0.56 per warrant. Based on the anti-dilution clause being triggered and the exercise price of the Brookstreet Warrants being revalued downward to $0.56, ASC 815-40-15 should have caused the Brookstreet Warrants to be treated and accounted for as a liability.
The anti-dilution provisions of the Brookstreet Warrants failed the criteria set by this ASC and therefore required reclassification from equity to liability. The reclassification resulted in the requirement to revalue the Brookstreet Warrants at each reporting period with a corresponding charge or credit to the statement of operations. Valuation of the warrants was estimated using the Monte-Carlo simulation method using the following assumptions: stock price and warrant price as of the valuation date, the Company’s historical stock price, interest rate on U.S. treasury notes, dividend rate derived from the Series D Preferred Stock, warrant expiration; simulated as a daily interval and anti-dilution impact if the Company had to raise capital below $0.25 per share. The reclassification and valuation of the warrants resulted in warrant liabilities of zero as of September 30, 2012 and December 31, 2012. In addition, in the three and nine months ended September 30, 2013 and 2012, we recorded income of $0, $0, $0 and $38,000, respectively, in our consolidated condensed statements of operations related to the change in the fair value of warrants.
The 1,721,629 Brookstreet Warrants outstanding as of December 31, 2011 expired on February 14, 2012, and the Company recorded $38,000 in the nine months ending September 30, 2012 to reduce the fair market value of the warrants to zero.
Warrants issued with other financings
During 2007 and 2008, the Company entered into various agreements to borrow working capital and as part of these agreements, the Company issued warrants to the holders to purchase common stock. The Company issued 1,400,000 warrants to YKA Partners, an affiliated company of our former Co-Chairman of the Board with an exercise price of $0.25 per share, all of which expired unexercised in August 2013.
Warrants issued with Preferred Stock
During 2008, in connection with the Company’s fund raising efforts, two warrants to purchase shares of common stock were issued with the purchase of one share of Series A Preferred Stock, resulting in the issuance of an additional 2,000,000 common stock warrants. In addition, two warrants to purchase shares of common stock were issued with the purchase of one share of Series B Preferred Stock, resulting in the issuance of an additional 1,100,000 common stock warrants. As of December 31, 2010, 400,000 warrants related to the Series A Preferred Stock were converted into 800,000 common shares.
1,600,000 warrants related to the Series A Preferred Stock expired in January, 2013. As of September 30, 2013 and December 31, 2012, there were 0 and 300,000 warrants related to the Series B Preferred Stock outstanding, respectively with an exercise price of $0.20 per share. The warrants related to the Series B Preferred Stock expired unexercised in July 2013.
Warrants issued with Common Stock
In conjunction with the Company’s sale of 10,125,000 shares of common stock on January 22, 2013, the Company issued warrants convertible into 5,062,500 shares of common stock at an exercise price of $0.20 per share. The warrants have a five year term.
On March 12, 2013 the Company issued warrants convertible into 2,500,000 shares of common stock in conjunction with the sale of 5,000,000 shares of common stock. These warrants have a five year term and an exercise price of $0.20 per share.
On July 24, 2013 the Company sold 20,000,000 Units, with each Unit consisting of one share of common stock and one Series A Warrant. The Series A Warrants are convertible into 20,000,000 shares of common stock at an initial exercise price of $0.15 per share. The warrants have a five year term and were immediately exercisable. In addition, the Company issued 20,000,000 Series B Warrants each to purchase one Unit. The Series B Warrants were immediately exercisable at an initial exercise price of $0.15 per Unit, subject to adjustment and expired on October 24, 2013. The Units issuable upon exercise of the Series B Warrants consisted of 20,000,000 shares of common stock and 20,000,000 Series A Warrants, which are convertible into an additional 20,000,000 shares of common stock at an exercise price of $0.15 per share. All Series A Warrants expire on the fifth anniversary of the transaction close, July 24, 2018, regardless of the date the Series A Warrants were issued.
The Series B Warrants were immediately exercisable at an initial exercise price of $0.15, subject to adjustment. Beginning at the close of trading on the 60th trading day following the date of issuance, and effective beginning on the fifth trading day immediately preceding such 60th trading day, the Series B Warrants were exercisable at a per unit exercise price equal to the lower of (i) the then-effective exercise price per unit and (ii) 80% of the closing bid price of the Company’s common stock on such 60th trading day. If prior to the close of trading on the 60th trading day after the date of issuance (and on any of the five trading days immediately preceding such day), a holder of the Series B Warrants had delivered one or more exercise notices to the Company and paid all or any part of the exercise price with respect thereto, then on the first trading day immediately following such 60th trading day the Company was obligated to deliver to such holder an amount in cash equal to the positive difference (if any) between (x) the exercise price actually paid by such holder and (y) the product of (I) the aggregate number of units elected to be purchased in such exercise notices, multiplied by (II) 80% of the closing bid price of the Company’s common stock on such 60th trading day. The Series B Warrants expired at the close of business on the 65th trading day following the date of issuance, October 24, 2013. The Series B Warrants were issued separately from the common stock and the Series A Warrants included in the Units, and were transferable separately immediately thereafter. Series B Warrants were issued in certificated form only. Investors in the Offering received one Series B Warrant for each Unit purchased by them in the Offering. No additional consideration was paid by Investors for the Series B Warrants.
During the third quarter of 2013, 1,700,000 Series B Warrants were exercised for net proceeds of $242,000 resulting in the issuance of 1,700,000 Units comprised of 1,700,000 shares of common stock and 1,700,000 Series A Warrants. See Note 11, Subsequent Events for further information regarding the conclusion of the Series B Warrant transactions from October 1, 2013 to the expiration date of October 24, 2013.
The exercise price and number of shares of common stock issuable upon exercise of the Series A Warrants are subject to adjustment in the event of any stock dividends and splits, reverse stock split, stock dividend, recapitalization, reorganization or similar transaction, as described in the Series A Warrants. The Series A Warrants also contain full ratchet anti-dilution protection upon the issuance of any common stock, securities convertible into common stock, or certain other issuances at a price below the then existing exercise price of the Series A Warrants, with certain exceptions. The exercise price and number of Units issuable on exercise of the Series B Warrants are subject to adjustment in the event of any stock split, reverse stock split, stock dividend, recapitalization, reorganization or similar transaction, as described in the Series B Warrants.
The Series A Warrants are exercisable on a “cashless” basis in certain circumstances. In addition, in the event of a fundamental transaction that is (i) an all cash or substantially all cash transaction, (ii) a “Rule 13e 3 transaction” as defined in Rule 13e-3 under the Securities Exchange Act of 1934, as amended, or (iii) with certain limited exceptions, a fundamental transaction involving a person or entity not traded on The New York Stock Exchange, Inc., The NYSE MKT, The NASDAQ Global Select Market, The NASDAQ Global Market or The NASDAQ Capital Market, then the Company or any successor entity will pay at the holder’s option, exercisable at any time concurrently with or within 45 days after the consummation of the fundamental transaction, an amount of cash equal to the value of the Series A Warrant as determined in accordance with the Black Scholes option pricing model.
We account for our warrants in accordance with current accounting guidance, which defines how freestanding contracts that are indexed to and potentially settled in a Company’s own stock should be measured and classified. The authoritative accounting guidance prescribes that only warrants issued under contracts that cannot be net-cash settled and are both indexed to and settled in the Company’s common stock can be classified as equity. As the Series A and B Warrant agreements did not meet the specific conditions for equity classification, we are required to classify the fair value of the warrants issued as a liability, with subsequent changes in fair value to be recorded as income (loss) in the statement of operations upon revaluation of the fair value of warrant liability at each reporting period. Valuation of the Warrants was estimated at September 30, 2013 using the Monte-Carlo simulation model. The fair value is affected by changes in inputs to the model. The following assumptions were used as inputs to the model: stock price of $0.15 and warrant exercise price of $0.15 as of the valuation date; the Company’s historical stock price volatility of 87.7%; risk free interest rate on U.S. treasury notes of 1.33% for Series A Warrants, and .03% for Series B Warrants; a zero dividend rate; warrant expiration of 5 years for Series A and 0.07 years for the Series B Warrants; simulated as a daily interval and anti-dilution impact if the Company had to raise capital below $0.15 per share.
The fair value of the warrant liability at the issuance date exceeded the gross proceeds received for the common shares, Series A Warrants and the Series B Warrants by $1.39 million. The Series A Warrants, Series B Warrants, and Placement Agent Warrants had fair values of $1.72 million, $2.65 million and $115,000 at issuance, respectively. The classification and valuation of the warrants resulted in total warrant liabilities of $4.5 million and $4.4 million as of the issuance date of July 24, 2013 and the revaluation date of September 30, 2013, respectively. In addition, during the three and nine months ended September 30, 2013, we recorded income of $27,000, in our consolidated condensed statements of operations related to the change in fair value of the warrant liability due to the revaluation at September 30, 2013 and the change in fair value of the Series B Warrants at each exercise date. The Series B Warrants expired on October 24, 2013.
Warrants issued to BioTime
During June 2008, the Company entered into an agreement with BioTime, Inc. (“Bio Time”). Based on the agreement, Bio Time agreed to pay the Company an advance of $250,000 to produce, make, and distribute joint products (as defined in that agreement). As part of the agreement, the Company issued warrants for Bio Time to purchase 30,000 shares of the Company’s common stock at $0.25 per share. These warrants expired in December 2012.
Warrants issued in connection with SkinCare Marketing Agreement
In September 2011, the Company signed a Marketing Agreement (“agreement”) with an effective date of June 30, 2011, with a third party marketing organization. According to the terms of the agreement as described in Note 10 below, Commitments and Contingencies, under Marketing Arrangement and Agreement, the third party marketing organization would provide assistance to LSC to sell its skin care products through various specific proprietary mailings. The agreement provides for two tranches of common stock warrants to be issued by the Company for the benefit of the third party marketing organization for 100,000 shares each, with strike prices of $1.50 and $2.00, respectively, vesting over four quarters, and a warrant term of five years.
Accordingly, there were warrants for 100,000 shares of common stock at a strike price of $1.50 vested as of December 31, 2011 in connection with the agreement. In addition, as of September 30, 2012, there were 100,000 warrants vested with a strike price of $2.00. The Company valued the warrants issued in connection with the SkinCare Marketing Agreement using the Black-Scholes pricing model and the following assumptions: contractual terms of 5 years, an average risk free interest rate of 0.94%, a dividend yield of 0%, and volatility of 134%.
Outstanding warrants related to warrant transactions through September 30, 2013 were as follows:
	Preferred Stock						Common Stock			Units																										Price per Warrant
	Series A			Series B			Series A			Series B			Placement		YKA			BioTime			Bridge Loan			Brookstreet			Skin Care		Jan 2013		Mar-13		Total			Range		Weighted
													Agent		Loan						& non-cash						Marketing		Financing		Financing		Warrants					Average
																					Grants																	exercise price
Outstanding, December 31, 2009		2,000,000			1,100,000											1,400,000			30,000			1,629,623			3,405,929			—		—		—		9,565,552		$	0.25-0.80	$	0.45
2010
Issued																																		—
Exercised		(400,000	)		(600,000	)																(248,902	)		(1,645,772	)								(2,894,674	)		0.25-0.80		0.47
Forfeited/Cancelled																																		—
Outstanding, December 31, 2010		1,600,000			500,000											1,400,000			30,000			1,380,721			1,760,157			—		—		—		6,670,878		$	0.25-0.80	$	0.45
2011
Issued																												200,000						200,000			1.50-2.00		1.75
Exercised					(200,000	)																(62,800	)		(38,528	)								(301,328	)		0.25-0.80		0.4
Forfeited/Cancelled																																		—
Outstanding, December 31, 2011		1,600,000			300,000											1,400,000			30,000			1,317,921			1,721,629			200,000		—		—		6,569,550		$	0.25-2.00	$	0.49
2012
Issued																																		—
Exercised																																		—
Forfeited/Cancelled																			(30,000	)		(1,317,921	)		(1,721,629	)								(3,069,550	)	$	0.56-0.80		0.66
Outstanding, December 31, 2012		1,600,000			300,000			—			—					1,400,000			—			—			—			200,000		—		—		3,500,000		$	0.25-2.00	$	0.34
2013
Issued								21,700,000			20,000,000			666,666																5,062,500		2,500,000		49,929,166		$	0.15-0.20	$	0.16
Exercised											(1,700,000	)																						(1,700,000	)	$	0.15	$	0.15
Forfeited/Cancelled		(1,600,000	)		(300,000	)										(1,400,000	)																	(3,300,000	)	$	0.20-0.25	$	0.25
Outstanding, September 30, 2013		—			—			21,700,000			18,300,000			666,666		—			—			—			—			200,000		5,062,500		2,500,000		48,429,166		$	0.15-2.00	$	0.16

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	10. Commitments and Contingencies
	Leases
	We have established our primary research facility in 8,215 square feet of leased office and laboratory space in Oceanside, California. Our lease for this facility expires in August 2016. Our current base rent is $8,588 per month. The facility has leasehold improvements which include cGMP (current Good Manufacturing Practices) level clean rooms designed for the derivation of clinical-grade stem cells and their differentiated derivatives, research laboratories for our stem cell differentiation studies and segregated rooms for biohazard control and containment of human donor tissue. The monthly base rent will increase by 3% annually on the anniversary date of the agreement.
	In March 2011, we moved into a new manufacturing facility in Frederick, Maryland which we use for laboratory and administrative purposes. Our current base rent in the new facilities is $11,644 per month. The initial lease term expires December 31, 2015 and there is an option for an additional five years.
	On February 25, 2011, the Company entered into a lease agreement (the “Lease Agreement”) with S Real Estate Holdings LLC to allow the Company to expand into new corporate offices located at 5950 Priestly Drive, Carlsbad, California. The new building is used for administrative purposes, but could also be used for research and development purposes if such space is needed in the future. The lease covers approximately 4,653 square feet, which was occupied on or about March 1, 2011. The lease expires on February 29, 2016, subject to the Company’s right to extend the term for up to five additional years. The Company began rent payments in March 2011 once it occupied the facilities, at an initial rate of $5,118 per month. The lease was amended effective July 2011 and January 2013 to account for additional square footage occupied by Company personnel. As such, the initial monthly rate has increased to $11,492 per month. In addition, the monthly base rent will increase by 3% annually on the anniversary date of the agreement. The Company is also obligated to pay a portion of the utilities for the building, CC&R fees and increases in property tax and insurance.
	S Real Estate Holdings LLC is owned by Dr. Ruslan Semechkin, the Company’s Chief Science Officer and was previously owned by Dr. Andrey Semechkin, the Company’s Chief Executive Officer and Co-Chairman of the Board of Directors. The Lease Agreement was negotiated at arm’s length and was reviewed by the Company’s outside legal counsel. The terms of the lease were reviewed by a committee of independent directors, and the Company believes that, in total, those terms are consistent with the terms that could be obtained for comparable facilities from an unaffiliated party.
	Future minimum lease payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of September 30, 2013, are as follows (in thousands):
		Amount
	2013 (remaining three months)	$	97
	2014		386
	2015		397
	2016		101
	2017		3
	Total	$	984
	Marketing Arrangement and Agreement
	The Company signed a Term Sheet (“arrangement”) in late 2010 with a third party marketing organization that would serve as a consultant and assist in marketing for Lifeline Skin Care, Inc., (“LSC”) a wholly-owned subsidiary of International Stem Cell, to sell its skin care products through various proprietary mailings. As part of the arrangement, there were various phases and objectives to accomplish, one of which was the potential formation of a joint venture in the future between the parties. Based on the arrangement, LSC paid to the marketing organization 40% of net profits (as defined in the arrangement) generated from the proprietary mailings.
	In September 2011, the Company signed a Marketing Agreement (“agreement”) with an effective date of June 30, 2011, superseding the terms of the arrangement with the third party marketing organization. According to the agreement, the third party marketing organization will continue to provide assistance to LSC to sell skin care products through various specific proprietary mailings. In exchange for such services, the Company will pay 20% of net revenues for Direct Sales (as defined in the agreement) generated from the proprietary mailings. In addition, the Company agreed to pay 10% of net revenues for Referral Sales. The agreement specifies that the parties do not intend to create a joint venture, and that either party may terminate the agreement upon 30-day written notice. In addition, the agreement provides for two tranches of common stock warrants to be issued by the Company for the benefit of the third party marketing organization for 100,000 shares each, with strike prices of $1.50 and $2.00, respectively, with vesting over four quarters, and warrant term of five years. Subsequently in July 2012, we renegotiated the commission structure to reflect slightly lower rates, 18% on net revenues derived from direct sales and 9% on net revenues derived from referral sales. The Company recognized $0, $0, $36,000 and $73,000 in stock-based compensation from warrants issued for services during the three and nine months ended September 30, 2013 and 2012, respectively. During the three and nine months ended September 30, 2013, LSC incurred marketing expenses of $18,000 and $61,000, respectively, under the terms of this arrangement and agreement. For the same periods in 2012, we recorded $32,000 and $117,000, respectively, as marketing expenses related to this consultant.
	Customer Concentration
	During the three and nine months ended September 30, 2013 one major customer accounted for 24% and 18% of our consolidated revenues, respectively, and another major customer accounted for 13% and 12% of our consolidated revenues, respectively. During the three and nine months ended September 30, 2012, one major customer, accounted for 17% and 15% of our consolidated revenues, respectively, and another major customer accounted for 13% and 10% of our consolidated revenues, respectively.

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2013
Subsequent Events [Abstract]	'
Subsequent Events	'
	11. Subsequent Events
	Series B Warrant exercises
	Subsequent to September 30, 2013, the Company received net proceeds of an additional $2.1 million upon the exercise of 15,054,822 of the Series B Warrants issued in July 2013 for 15,054,822 additional Units, but prior to the expiration of the Series B Warrants on October 24, 3013. The total additional Units consisted of 15,054,822 shares of common stock and 15,054,822 Series A Warrants. Of the subsequent exercises, Dr. Andrey Semechkin, the Company’s Co-Chairman and Chief Executive Officer, exercised 2,754,821 Series B Warrants, and Ruslan Semechkin, the Company’s Chief Science Officer, exercised 667,667 Series B Warrants for an aggregate price of $497,000.
	Series B Price adjustment
	The Series B Warrants were subject to an exercise price adjustment on the 60th trading day following issuance in July 2013. On October 17, 2013, the adjustment date, the adjusted exercise price was calculated at a 20% discount to the closing bid price on the adjustment date. The closing bid price on the adjustment date was $0.1815 per share, which resulted in an adjusted exercise price of $0.1452 per Unit. This adjusted exercise price was retroactively applied to all exercises from the period of October 10th through to the expiration date of October 24th. Of the 15,054,822 Series B Warrants exercised subsequent to September 30, 2013, there were 12,304,822 subject to the adjusted exercise price of $0.1452 per Unit for net proceeds of approximately $1.7 million. The remaining 2,750,000 were exercised prior to the adjustment date at $0.15 per Unit for net proceeds of approximately $0.4 million.
	Expiration of Series B Warrants
	On October 24, 2013, the remaining 3,245,178 Series B Warrants expired unexercised. Following the expiration of the Series B Warrants, total outstanding warrants were 45,183,988, which the Company has reserved 45,850,654 shares of common stock for future issuance. Total Series A Warrants outstanding are 36,754,822 following the total exercises of the Series B Warrants.

Organization_and_Significant_A1

Organization and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Business Combination and Corporate Restructure	'
	Business Combination and Corporate Restructure
	BTHC III, Inc. (“BTHC III” or the “Company”) was organized in Delaware in June 2005 as a shell company to effect the reincorporation of BTHC III, LLC, a Texas limited liability company. On December 28, 2006, the Company effected a Share Exchange pursuant to which it acquired all of the stock of International Stem Cell Corporation, a California corporation (“ISC California”). After giving effect to the Share Exchange, the stockholders of ISC California owned 93.7% of issued and outstanding shares of common stock. As a result of the Share Exchange, ISC California is now a wholly-owned subsidiary, though for accounting purposes it was deemed to have been the acquirer in a “reverse merger.” In the reverse merger, BTHC III is considered the legal acquirer and ISC California is considered the accounting acquirer. On January 29, 2007, the Company changed its name from BTHC III, Inc. to International Stem Cell Corporation.
	Lifeline Cell Technology, LLC (“LCT”) was formed in the State of California on August 17, 2001. LCT is in the business of developing and manufacturing purified primary human cells and optimized reagents for cell culture. LCT’s scientists have used a technology, called basal medium optimization, to systematically produce products designed to culture specific human cell types and to elicit specific cellular behaviors. These techniques also produce products that do not contain non-human animal proteins, a feature desirable to the research and therapeutic markets. LCT distinguishes itself in the industry by having in place scientific and manufacturing staff with the experience and knowledge to set up systems and facilities to produce a source of consistent, standardized, non-human animal protein free cell products, some of which are suitable for FDA approval.
	On July 1, 2006, LCT entered into an agreement among LCT, ISC California and the holders of membership units and warrants. Pursuant to the terms of the agreement, all the membership units in LCT were exchanged for 20,000,000 shares of ISC California common stock and for ISC California’s assumption of LCT’s obligations under the warrants. LCT became a wholly-owned subsidiary of ISC California.
	Lifeline Skin Care, Inc. (“LSC”) was formed in the State of California on June 5, 2009 and is a wholly-owned subsidiary of ISC California. LSC develops, manufactures and markets cosmeceutical products, utilizing an extract derived from our human parthenogenetic stem cell technologies.
Going Concern	'
	Going Concern
	The Company continues in the development stage and as such has accumulated losses from inception and expects to incur additional losses in the near future. The Company needs to raise additional working capital. The timing and degree of any future capital requirements will depend on many factors. Currently, the Company’s burn rate is approximately $470,000 per month, excluding capital expenditures and patent costs averaging $57,000 per month. There can be no assurance that the Company will be successful in maintaining its normal operating cash flow, and that such cash flows will be sufficient to sustain the Company’s operations through the first quarter of 2014. Based on the above, there is substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements were prepared assuming that the Company is a going concern. The condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.
	Management’s plans in regard to these matters are focused on managing its cash flow, the proper timing of its capital expenditures, and raising additional capital or financing in the future. In the first quarter of 2013, to obtain funding for working capital purposes, the Company sold a total of 16,325,000 shares of common stock raising net proceeds of approximately $3.3 million. In July 2013, we closed a financing transaction contemplated by our S-1 Registration Statement on file with the U.S. Securities and Exchange Commission. We issued 20,000,000 Units in this transaction, raising net proceeds of approximately $2.4 million. Each Unit issued consists of a share of common stock and a Series A Warrant. Each purchaser also received a Series B Warrant for each Unit purchased. During the third quarter of 2013, the Company received net proceeds of $242,000 upon the exercise of 1,700,000 Series B Warrants for 1,700,000 additional Units. Subsequent to September 30, 2013, the Company received additional net proceeds of $2.1 million upon the exercise of 15,054,822 Series B Warrants for 15,054,822 additional Units, but prior to the expiration of the Series B Warrants on October 24, 2013. For further discussion regarding these transactions, see Note 6, Capital Stock and Note 11, Subsequent Events.
Basis of Presentation	'
	Basis of Presentation
	International Stem Cell Corporation was formed in June 2006. BTHC III, Inc. was a shell company that had no operations and no net assets. For accounting purposes the acquisition has been treated as a recapitalization of BTHC III with ISC California as the accounting acquirer (reverse acquisition). The historical statements prior to June 2006 are those of Lifeline Cell Technology, LLC, the wholly-owned subsidiary of ISC California.
	The Company is a development-stage company with no revenue generated from its principal operations in therapeutic and biomedical products development through research and development efforts. To date, the Company has generated limited and unpredictable revenue to support its core therapeutic research and development efforts.
	The accompanying unaudited condensed consolidated financial statements included herein have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q.
	These financial statements do not include all information and notes required by generally accepted accounting principles for complete financial statements. However, except as disclosed herein, there has been no material change in the information disclosed in the notes to consolidated financial statements included in the annual report on Form 10-K of International Stem Cell Corporation and Subsidiaries for the year ended December 31, 2012. When used in these notes, the terms “Company,” “we,” “us,” or “our” mean International Stem Cell Corporation and all entities included in our unaudited condensed consolidated financial statements.
	In the opinion of management, the unaudited condensed consolidated financial information for the interim periods presented reflects all adjustments, consisting of only normal and recurring adjustments, necessary for a fair presentation of the Company’s consolidated results of operations, financial position and cash flows. The unaudited condensed consolidated financial statements and the related notes should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2012 included in the Company’s annual report on Form 10-K. Operating results for interim periods are not necessarily indicative of the operating results for any other interim period or an entire year.
Principles of Consolidation	'
	Principles of Consolidation
	The Company’s consolidated financial statements include the accounts of International Stem Cell Corporation and its subsidiaries after intercompany balances and transactions have been eliminated.
	The preparation of financial statements requires that management make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates.
Cash Equivalents	'
	Cash Equivalents
	The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents.
Restricted Cash	'
	Restricted Cash
	The Company is required to maintain $50,000 in a restricted certificate of deposit account in order to fully collateralize a revolving credit card account.
Inventories	'
	Inventories
	Inventories are accounted for using the first-in, first-out (FIFO) method for LSC products, and specific identification method for LCT products. Inventory balances are stated at the lower of cost or market. Laboratory supplies used in the research and development process are expensed as consumed. Inventory is reviewed periodically for product expiration and obsolescence and is adjusted accordingly.
Accounts Receivable	'
	Accounts Receivable
	Trade accounts receivable are recorded at the net invoice value and are not interest bearing. Accounts receivable primarily consist of trade accounts receivable from the sales of LCT’s products, timing of cash receipts by the Company related to LSC credit card sales to customers, as well as LSC trade receivable amounts related to spa and distributor sales. The Company considers receivables past due based on the contractual payment terms. The Company reviews its exposure to accounts receivable and reserves specific amounts if collectability is no longer reasonably assured. As of September 30, 2013 and December 31, 2012, the Company had an allowance for doubtful accounts totaling $19,000 and $4,000, respectively.
Property and Equipment	'
	Property and Equipment
	Property and equipment are stated at cost. The provision for depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets, generally over five years. The costs of major remodeling and leasehold improvements are capitalized and amortized over the shorter of the remaining term of the lease or the life of the asset.
Intangible Assets	'
	Intangible Assets
	Intangible assets consist of acquired research and development rights used in research and development, and capitalized legal fees related to the acquisition, filing, maintenance, and defense of patents. Patent or patent license amortization only begins once a patent license is acquired or a patent is issued by the appropriate authoritative bodies. In the period in which a patent application is rejected or efforts to pursue the patent are abandoned, all the related accumulated costs are expensed. Patents and patent licenses are recorded at cost of $2,531,000 and $2,083,000 at September 30, 2013 and December 31, 2012, respectively, and are amortized on a straight-line basis over the shorter of the lives of the underlying patents or the useful life of the license. Amortization expense for the three months ended September 30, 2013 and 2012 amounted to $16,000 and $16,000, respectively, while amortization expense for the nine months ended September 30, 2013 and 2012 was $46,000 and $49,000, respectively. All amortization expense related to intangible assets is included in research and development expense. Accumulated amortization as of September 30, 2013 and December 31, 2012 was $495,000 and $449,000, respectively. Additional information regarding patents and patent licenses is included in Note 4.
Long-lived Asset Impairment	'
	Long-lived Asset Impairment
	The Company reviews long-lived assets for impairment when events or changes in business conditions indicate that their carrying value may not be recovered, and at least annually. The Company considers assets to be impaired and writes them down to fair value if expected associated undiscounted cash flows are less than the carrying amounts. Fair value is the present value of the associated cash flows. The Company did not recognize material impairments on its long-lived assets during the three and nine months ended September 30, 2013 and 2012.
Product Sales	'
	Product Sales
	The Company recognizes revenue from product sales at the time of shipment to the customer, provided no significant obligations remain and collection of the receivable is reasonably assured. If the customer has a right of return, the Company recognizes product revenues upon shipment, provided that future returns can be reasonably estimated. In the case where returns cannot be reasonably estimated, revenue will be deferred until such estimates can be made or the right of return has expired. LSC’s revenue accounted for 49% and 48% of total revenue during the nine months ended September 30, 2013 and 2012, respectively. LCT contributed 51% and 52% of total revenue during the nine months ended September 30, 2013 and 2012, respectively.
Deferred Revenue	'
	Deferred Revenue
	The Company recognizes revenue from LSC products when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the seller’s price to the buyer is fixed or determinable, and collectability is reasonably assured. However, LSC products sold through web-based channels have a 30-day right of return guarantee and therefore, the Company defers all revenue associated with these product sales until the 30-day guarantee has expired. In addition, all costs associated with these product sales are reclassified against the deferred revenue account so that the net deferred revenue balance is presented. At September 30, 2013 and December 31, 2012, net deferred revenue totaled $156,000 and $233,000, respectively.
Cost of Sales	'
	Cost of Sales
	Cost of sales consists primarily of salaries and benefits associated with employee efforts expended directly on the production of the Company’s products and include related direct materials, general laboratory supplies and allocation of overhead. Certain of the agreements under which the Company has licensed technology will require the payment of royalties based on the sale of its future products. Such royalties will be recorded as a component of cost of sales. Additionally, the amortization of license fees or milestone payments related to developed technologies used in the Company’s products will be classified as a component of cost of sales to the extent such payments become due in the future.
Research and Development Costs	'
	Research and Development Costs
	Research and development costs, which are expensed as incurred, are primarily comprised of costs and expenses for salaries and benefits associated with research and development personnel, overhead and occupancy, contract services, and amortization of license costs for technology used in research and development with alternative future uses.
Registration Payment Arrangements	'
	Registration Payment Arrangements
	In accordance with applicable authoritative guidance, the Company is required to separately recognize and measure registration payment arrangements, whether issued as a separate agreement or included as a provision of a financial instrument or other agreement. Such payments include penalties for failure to effect a registration of securities.
Fair Value Measurements	'
	Fair Value Measurements
	On January 1, 2008, the Company adopted authoritative guidance for fair value measurements and fair value disclosures. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:
		Level 1	Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
		Level 2	Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability; and
		Level 3	Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).
	Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.
Income Taxes	'
	Income Taxes
	The Company accounts for income taxes in accordance with applicable authoritative guidance, which requires the Company to provide a net deferred tax asset/liability equal to the expected future tax benefit/expense of temporary reporting differences between book and tax accounting methods and any available operating loss or tax credit carryforwards.
Use of Estimates	'
	Use of Estimates
	The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements. Significant estimates include patent life (remaining legal life versus remaining useful life), inventory carrying values and transactions using the Black-Scholes option pricing model, e.g., warrants and stock options. Actual results could differ from those estimates.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The Company believes that the carrying value of its cash and cash equivalents, receivables, accounts payable and accrued liabilities as of September 30, 2013 and December 31, 2012 approximate their fair values because of the short-term nature of those instruments.
Income (Loss) Per Common Share	'
	Income (Loss) Per Common Share
	The computation of net loss per common share is based on the weighted average number of shares outstanding during each period. The computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the period plus the common stock equivalents, which would arise from the exercise of stock options and warrants outstanding using the treasury stock method and the average market price per share during the period. At September 30, 2013, there were 596,250 non-vested restricted shares, 67,395,832 shares issuable upon exercise of warrants, and 17,914,518 vested and 5,780,175 non-vested stock options outstanding; and at September 30, 2012, there were 335,000 non-vested restricted shares, 3,530,000 warrants, and 14,397,857 vested and 9,132,615 non-vested stock options outstanding. These restricted shares, options and warrants were not included in the diluted loss per share calculation because the effect would have been anti-dilutive.
Comprehensive Income	'
	Comprehensive Income
	Comprehensive income or loss includes all changes in equity except those resulting from investments by owners and distributions to owners. The Company did not have any items of comprehensive income or loss other than net loss from operations for the three and nine months ended September 30, 2013 and 2012 or the period from inception through September 30, 2013.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	There were no new accounting pronouncements during the nine months ended September 30, 2013, as compared to the recent accounting pronouncements described in the Annual Report on Form 10-K for the fiscal year ended December 31, 2012, that are of significance, or potential significance, to the Company.
Instruments under Embedded Features	'
	Implementation of Accounting Standards Code (ASC) 815-40-15, (formerly known as EITF 07-5 “Determining Whether an Instrument (or Embedded Feature) is Indexed to an Entity’s Own Stock Price”)
	The Accounting Standards Code (ASC) 815-40-15, with an effective date of December 15, 2008, should have been implemented as of January 1, 2009, and in future periods. This Issue applies to any freestanding financial instrument or embedded feature that has all the characteristics of a derivative as described in ASC 815-10-15-83, (previously paragraphs 6–9 of Statement 133) for purposes of determining whether that instrument or embedded feature qualifies for the first part of the scope exception in ASC 815-10-74 (previously paragraph 11(a) of Statement 133). This Issue also applies to any freestanding financial instrument that is potentially settled in an entity’s own stock, regardless of whether the instrument has all the characteristics of a derivative for purposes of determining whether the instrument is within the scope of ASC 815-40.

Organization_and_Significant_A2

Organization and Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Fair Value of Assets and Liabilities	'
	The table below sets forth a summary of the fair values of the Company’s assets and liabilities as of September 30, 2013 (in thousands).
		Total			Level 1		Level 2		Level 3
	ASSETS:
	Cash equivalents	$	5		$	5	$	—	$	—
	LIABILITIES:
	Fair value of warrant liability	$	4,389		$	—	$	—	$	4,389
	The table below sets forth a summary of the fair values of the Company’s assets and liabilities as of December 31, 2012 (in thousands).
		Total			Level 1		Level 2		Level 3
	ASSETS:
	Cash equivalents	$	5		$	5	$	—	$	—
Fair Value Measurement and Unobservable Rollforward Activity of Liabilities	'
	The following table displays the rollforward activity of liabilities with inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity):
		Fair Value of Warrant Liability
	Beginning balance at December 31, 2011	$	38
	Issuances		—
	Adjustments to estimated fair value		(38	)
	Ending balance at December 31, 2012		—
	Issuances		4,635
	Exercises		(219	)
	Adjustments to estimated fair value		(27	)
	Ending balance at September 30, 2013	$	4,389

Inventory_Tables

Inventory (Tables)	9 Months Ended
	Sep. 30, 2013
Inventory Disclosure [Abstract]	'
Summary of the Components of Inventories	'
	The components of inventories are as follows (in thousands):
		September 30,			December 31,
		2013			2012
	Raw materials	$	141		$	276
	Work in process		428			211
	Finished goods		868			748
	Total		1,437			1,235
	Less: allowance for inventory obsolescence		(77	)		(36	)
	Inventory, net	$	1,360		$	1,199

Property_and_Equipment_Tables

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2013
Property Plant And Equipment [Abstract]	'
Summary of Property and Equipment	'
	Property and equipment consists of the following (in thousands):
		September 30,			December 31,
		2013			2012
	Machinery and equipment	$	1,092		$	1,072
	Computer equipment		321			347
	Office equipment		225			225
	Leasehold improvements		839			830
			2,477			2,474
	Less: accumulated depreciation and amortization		(1,626	)		(1,340	)
	Property and equipment, net	$	851		$	1,134

Patent_Licenses_Tables

Patent Licenses (Tables)	9 Months Ended
	Sep. 30, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Summary of Future Amortization Expense Related to Our Intangible Assets Subject to Amortization	'
	At September 30, 2013, future amortization expense related to our intangible assets subject to amortization is expected to be as follows (in thousands):
		Amount
	2013 (remaining three months)	$	15
	2014		61
	2015		61
	2016		61
	2017		61
	Thereafter		1,724
	Total	$	1,983

Advances_Tables

Advances (Tables)	9 Months Ended
	Sep. 30, 2013
Text Block [Abstract]	'
Summary of Advances to Related Party	'
	As of September 30, 2013 no revenues were realized from this agreement.
		September 30,		December 31,
		2013		2012
	BioTime, Inc. (in thousands)	$	250	$	250

Capital_Stock_Tables

Capital Stock (Tables)	9 Months Ended
	Sep. 30, 2013
Equity [Abstract]	'
Summary of Shares of Common Stock Reserved for Future Issuance	'
	At September 30, 2013, the Company had shares of common stock reserved for future issuance as follows:
	Options outstanding	23,694,693
	Options available for future grant	16,032,480
	Convertible preferred stock	39,899,151
	Warrants	67,395,832
		147,022,156

Stock_Options_and_Warrants_Tab

Stock Options and Warrants (Tables)	9 Months Ended
	Sep. 30, 2013
Text Block [Abstract]	'
Fair Value of Stock Option Award	'
	The fair value of options granted is estimated at the date of grant using a Black-Scholes option-pricing model with the following weighted-average assumptions for the three and nine months ended September 30, 2013 and 2012:
		Three Months			Nine Months			Three Months			Nine Months
		Ended			Ended			Ended			Ended
		September 30,			September 30,			September 30,			September 30,
		2013			2013			2012			2012
	Significant assumptions (weighted-average):
	Risk-free interest rate at grant date		0	%		0.95	%		0.88	%		0.94	%
	Expected stock price volatility		0	%		118.34	%		124.93	%		123.63	%
	Expected dividend payout		0	%		0	%		0	%		0	%
	Expected option life-years based on management’s estimate		0.0 yrs			6.1 yrs			5.6 yrs			5.7 yrs
Summary of Changes in Options Outstanding and Related Exercise Prices	'
	The following table summarizes options outstanding as of September 30, 2013:
	Options Outstanding										Options Exercisable and vested
	Exercise Prices	Number Outstanding			Weighted			Weighted Average			Number			Weighted Average		Weighted Average
					Average			Exercise Price			Exercisable			Remaining		Exercise Price
					Remaining									Contractual Life
					Contractual Life									(Years)
					(Years)
	$0.22-$0.50		5,198,300			7.31		$	0.37			2,612,100			5.56	$	0.42
	$0.51-$0.75		9,265,293			6.18		$	0.62			8,363,918			6.15	$	0.62
	$0.76-$1.00		1,895,000			3.77		$	0.98			1,791,000			3.52	$	0.99
	$1.01-$1.25		335,000			7.59		$	1.1			253,600			7.59	$	1.1
	$1.26-$1.50		1,171,100			6.37		$	1.31			926,700			6.24	$	1.32
	$1.51-$3.20		5,830,000			7.08		$	1.94			3,967,200			7	$	1.95
			23,694,693			6.49		$	0.96			17,914,518			6.02	$	0.96
Summary of the Changes in Options Outstanding and the Related Exercise Prices for the Shares of the Company's Common Stock Options Issued	'
	The following table summarizes the changes in options outstanding and the related exercise prices for the Company’s common stock options issued:
		Number of			Weighted
		Shares issued			Average Exercise
		under			Price Per
		2006 Plan and			Share
		2010 Plan
	Outstanding at December 31, 2011		14,730,207		$	1.26
	Granted		2,398,000		$	0.38
	Exercised		(17,500	)	$	0.22
	Canceled or expired		(1,987,807	)	$	0.78
	Outstanding at December 31, 2012		15,122,900		$	1.18
	Granted		1,352,500		$	0.27
	Exercised		—		$	—
	Canceled or expired		(390,000	)	$	0.56
	Outstanding at September 30, 2013		16,085,400		$	1.12
		Number of			Weighted
		Shares issued			Average Exercise
		outside			Price Per
		the Plan			Share
	Outstanding at December 31, 2011		8,254,232		$	0.65
	Granted		—		$	—
	Exercised		—		$	—
	Canceled or expired		—		$	—
	Outstanding at December 31, 2012		8,254,232		$	0.65
	Granted		—		$	—
	Exercised		—		$	—
	Canceled or expired		(644,939	)	$	1
	Outstanding at September 30, 2013		7,609,293		$	0.62
Summary of Outstanding Warrants Related to Warrant Transactions	'
	Outstanding warrants related to warrant transactions through September 30, 2013 were as follows:
		Preferred Stock						Common Stock			Units																										Price per Warrant
		Series A			Series B			Series A			Series B			Placement		YKA			BioTime			Bridge Loan			Brookstreet			Skin Care		Jan 2013		Mar-13		Total			Range		Weighted
														Agent		Loan						& non-cash						Marketing		Financing		Financing		Warrants					Average
																						Grants																	exercise price
	Outstanding, December 31, 2009		2,000,000			1,100,000											1,400,000			30,000			1,629,623			3,405,929			—		—		—		9,565,552		$	0.25-0.80	$	0.45
	2010
	Issued																																		—
	Exercised		(400,000	)		(600,000	)																(248,902	)		(1,645,772	)								(2,894,674	)		0.25-0.80		0.47
	Forfeited/Cancelled																																		—
	Outstanding, December 31, 2010		1,600,000			500,000											1,400,000			30,000			1,380,721			1,760,157			—		—		—		6,670,878		$	0.25-0.80	$	0.45
	2011
	Issued																												200,000						200,000			1.50-2.00		1.75
	Exercised					(200,000	)																(62,800	)		(38,528	)								(301,328	)		0.25-0.80		0.4
	Forfeited/Cancelled																																		—
	Outstanding, December 31, 2011		1,600,000			300,000											1,400,000			30,000			1,317,921			1,721,629			200,000		—		—		6,569,550		$	0.25-2.00	$	0.49
	2012
	Issued																																		—
	Exercised																																		—
	Forfeited/Cancelled																			(30,000	)		(1,317,921	)		(1,721,629	)								(3,069,550	)	$	0.56-0.80		0.66
	Outstanding, December 31, 2012		1,600,000			300,000			—			—					1,400,000			—			—			—			200,000		—		—		3,500,000		$	0.25-2.00	$	0.34
	2013
	Issued								21,700,000			20,000,000			666,666																5,062,500		2,500,000		49,929,166		$	0.15-0.20	$	0.16
	Exercised											(1,700,000	)																						(1,700,000	)	$	0.15	$	0.15
	Forfeited/Cancelled		(1,600,000	)		(300,000	)										(1,400,000	)																	(3,300,000	)	$	0.20-0.25	$	0.25
	Outstanding, September 30, 2013		—			—			21,700,000			18,300,000			666,666		—			—			—			—			200,000		5,062,500		2,500,000		48,429,166		$	0.15-2.00	$	0.16

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Summary of Future Minimum Lease Payments Required under Operating Leases that Have Initial or Remaining Non-Cancelable Lease Terms in Excess of One Year	'
	Future minimum lease payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of September 30, 2013, are as follows (in thousands):
		Amount
	2013 (remaining three months)	$	97
	2014		386
	2015		397
	2016		101
	2017		3
	Total	$	984

Organization_and_Significant_A3

Organization and Significant Accounting Policies - Additional Information (Detail) (USD $)

1 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

0 Months Ended

9 Months Ended

Jul. 31, 2013

Sep. 30, 2013

Mar. 12, 2013

Jan. 22, 2013

Dec. 31, 2012

Dec. 31, 2007

Dec. 31, 2006

Jul. 01, 2006

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Jul. 19, 2013

Sep. 30, 2013

Oct. 24, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Mar. 31, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Research and Development Expense [Member]

Research and Development Expense [Member]

Research and Development Expense [Member]

Research and Development Expense [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Subsequent Event [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Warrants [Member]

Warrants [Member]

Working capital [Member]

BTHC III [Member]

Skin Care [Member]

Skin Care [Member]

Cell Technology [Member]

Cell Technology [Member]

Series B Warrants [Member]

Item Effected [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of ownership in issued and outstanding shares of common stock parent Company

'

93.70%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants in subsidiary Company

'

'

'

'

'

'

'

20,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Burn rate

'

$470,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Patent costs

'

57,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares issued

'

134,169,565

5,000,000

10,125,000

87,388,815

1,370,000

1,350,000

'

'

'

'

'

'

'

'

'

'

'

'

16,325,000

'

'

'

'

'

Common stock value

'

134,000

1,000,000

2,025,000

87,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,300,000

'

'

'

'

'

Proceeds from issuance of common stock and warrants

2,400,000

'

'

'

'

'

'

'

'

'

'

'

'

242,000

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock and warrants

20,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exercise

'

'

'

'

'

'

'

'

'

'

'

'

'

1,700,000

15,054,822

'

'

'

'

'

'

'

'

'

'

Additional net proceeds from issuance of common stock and warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,100,000

'

'

'

'

'

'

'

'

'

'

Expiration date of warrants

'

'

'

'

'

'

'

'

'

'

'

'

24-Oct-13

'

24-Oct-13

'

'

'

'

'

'

'

'

'

'

Reverse acquisition net assets acquired

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

Reverse acquisition net income loss

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

Restricted cash

'

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Allowance for doubtful accounts

'

19,000

'

'

4,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated useful life of property and equipment

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Patents and patent licenses

'

2,531,000

'

'

2,083,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization expense

'

'

'

'

'

'

'

'

16,000

16,000

46,000

49,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Accumulated amortization

'

495,000

'

'

449,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of revenue contributed

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

49.00%

48.00%

51.00%

52.00%

Period of right of return guarantee

'

'30 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net deferred revenue

'

$156,000

'

'

$233,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Non-vested stock options outstanding

'

5,780,175

'

'

'

'

'

'

'

'

'

'

'

'

'

596,250

335,000

'

9,132,615

'

'

'

'

'

'

Shares of common stock reserved for future issuance net

'

147,022,156

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

67,395,832

3,530,000

'

'

'

'

'

'

Vested stock options outstanding

'

17,914,518

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

14,397,857

'

'

'

'

'

'

Organization_and_Significant_A4

Organization and Significant Accounting Policies - Fair Value of Assets and Liabilities (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
ASSETS:	'	'	'
Cash equivalents	$5	$5	'
LIABILITIES:	'	'	'
Fair value of warrant liability	4,389	'	38
Level 1 [Member]	'	'	'
ASSETS:	'	'	'
Cash equivalents	5	5	'
LIABILITIES:	'	'	'
Fair value of warrant liability	'	'	'
Level 2 [Member]	'	'	'
ASSETS:	'	'	'
Cash equivalents	'	'	'
LIABILITIES:	'	'	'
Fair value of warrant liability	'	'	'
Level 3 [Member]	'	'	'
ASSETS:	'	'	'
Cash equivalents	'	'	'
LIABILITIES:	'	'	'
Fair value of warrant liability	$4,389	'	'

Organization_and_Significant_A5

Organization and Significant Accounting Policies - Fair Value Measurement and Unobservable Rollforward Activity of Liabilities (Detail) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Fair Value Disclosures [Abstract]	'	'
Beginning balance	'	$38
Issuances	4,635	'
Exercises	-219	'
Adjustments to estimated fair value	-27	-38
Ending balance	$4,389	'

Inventory_Summary_of_the_Compo

Inventory - Summary of the Components of Inventories (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw materials	$141	$276
Work in process	428	211
Finished goods	868	748
Total	1,437	1,235
Less: allowance for inventory obsolescence	-77	-36
Inventory, net	$1,360	$1,199

Property_and_Equipment_Summary

Property and Equipment - Summary of Property and Equipment (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Depreciation and Amortization Expenses For Property Plant And Equipment [Line Items]	'	'
Property and equipment, gross	$2,477	$2,474
Less: accumulated depreciation and amortization	-1,626	-1,340
Property and equipment, net	851	1,134
Machinery and Equipment [Member]	'	'
Depreciation and Amortization Expenses For Property Plant And Equipment [Line Items]	'	'
Property and equipment, gross	1,092	1,072
Computer Equipment [Member]	'	'
Depreciation and Amortization Expenses For Property Plant And Equipment [Line Items]	'	'
Property and equipment, gross	321	347
Office Equipment [Member]	'	'
Depreciation and Amortization Expenses For Property Plant And Equipment [Line Items]	'	'
Property and equipment, gross	225	225
Leasehold Improvements [Member]	'	'
Depreciation and Amortization Expenses For Property Plant And Equipment [Line Items]	'	'
Property and equipment, gross	$839	$830

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Property Plant And Equipment Useful Life And Values [Abstract]	'	'	'	'
Depreciation expenses	$100,000	$106,000	$301,000	$320,000

Patent_Licenses_Additional_Inf

Patent Licenses - Additional Information (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013
Patent Licenses [Line Items]	'
Option and license fees	$340,000
Additional option fees	22,500
Additional license fees	400,000
Cash proceeds	5,000,000
Patent acquisition costs	1,730,000
Convertible Notes Payable [Member]	'
Patent Licenses [Line Items]	'
Interest rate	10.00%
UMass IP [Member]	'
Patent Licenses [Line Items]	'
Net sales of product reduced	0.25%
UMass IP [Member] | Minimum [Member]	'
Patent Licenses [Line Items]	'
Obligation to pay royalties (Ranged)	6.00%
UMass IP [Member] | Maximum [Member]	'
Patent Licenses [Line Items]	'
Obligation to pay royalties (Ranged)	12.00%
ACT IP [Member]	'
Patent Licenses [Line Items]	'
Patent acquisition costs	$747,000

Patent_Licenses_Summary_of_Fut

Patent Licenses - Summary of Future Amortization Expense Related to Our Intangible Assets Subject to Amortization (Detail) (USD $)	Sep. 30, 2013
In Thousands, unless otherwise specified
Goodwill And Intangible Assets Disclosure [Abstract]	'
2013	$15
2014	61
2015	61
2016	61
2017	61
Thereafter	1,724
Total	$1,983

Advances_Additional_Informatio

Advances - Additional Information (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Jun. 18, 2008
Related Party Transactions [Abstract]	'	'	'
Advances of related party	$250,000	$250,000	$250,000
Specified amount of revenue to be utilized for advances	'	'	250,000
Revenue realized from agreement	$0	'	'

Advances_Summary_of_Advances_t

Advances - Summary of Advances to Related Party (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Jun. 18, 2008
In Thousands, unless otherwise specified
Related Party Transaction Due From To Related Party [Line Items]	'	'	'
Advances of related party	$250	$250	$250
BioTime, Inc. [Member]	'	'	'
Related Party Transaction Due From To Related Party [Line Items]	'	'	'
Advances of related party	$250	$250	'

Capital_Stock_Additional_Infor

Capital Stock - Additional Information (Detail) (USD $)	1 Months Ended	12 Months Ended
	Oct. 31, 2006	Dec. 31, 2007	Aug. 31, 2007	Dec. 31, 2006	Sep. 30, 2013	Jul. 19, 2013	Mar. 12, 2013	Jan. 22, 2013	Dec. 31, 2012	31-May-12	Dec. 27, 2006
Class of Stock [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Common stock, shares authorized	'	'	'	200,000,000	300,000,000	'	'	'	300,000,000	300,000,000	200,000,000
Preferred stock, shares authorized	'	'	'	20,000,000	'	'	'	'	'	'	20,000,000
Common stock, par value	'	'	'	$0.00	$0.00	$0.00	'	'	$0.00	'	$0.00
Preferred stock, par value	'	'	'	$0.00	'	'	'	'	'	'	$0.00
Stock split approved	4.42	'	'	'	'	'	'	'	'	'	'
Common stock, shares outstanding	'	'	'	'	134,169,565	'	'	'	87,388,815	'	'
Share exchange ratio under share exchange agreement	1	'	'	'	'	'	'	'	'	'	'
Description of stock split arrangement	'	'	'	'In October 2006, the board of directors of BTHC III approved a stock split of 4.42 shares to 1.	'	'	'	'	'	'	'
Common stock, shares issued	'	1,370,000	'	1,350,000	134,169,565	'	5,000,000	10,125,000	87,388,815	'	'
Stock issued during period shares issued for legal consulting	'	'	'	350,000	'	'	'	'	'	'	'
Stock issued during period shares issued for contract to provide investor relations services	'	'	'	1,000,000	'	'	'	'	'	'	'
Investor relations services contract duration	'	'	'1 year	'	'	'	'	'	'	'	'
Net proceeds from sales	'	$1,157,000	'	'	'	'	'	'	'	'	'
Selling agent for the private placement	'	274,000	'	'	'	'	'	'	'	'	'
Convertible shares of common stock	'	$1	'	'	'	'	'	'	'	'	'
Maximum [Member]	'	'	'	'	'	'	'	'	'	'	'
Class of Stock [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Common stock, shares outstanding	2,209,993	'	'	'	'	'	'	'	'	'	'
Convertible shares of common stock	'	'	'	'	$0.15	'	'	'	'	'	'
Minimum [Member]	'	'	'	'	'	'	'	'	'	'	'
Class of Stock [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Common stock, shares outstanding	500,000	'	'	'	'	'	'	'	'	'	'

Capital_Stock_Series_A_Preferr

Capital Stock - Series A Preferred Stock - Additional Information (Detail) (USD $)

Sep. 30, 2013

Mar. 12, 2013

Jan. 22, 2013

Dec. 31, 2012

Dec. 31, 2007

Dec. 31, 2009

Sep. 30, 2013

Mar. 31, 2012

Sep. 30, 2013

Dec. 31, 2008

Jan. 15, 2008

Mar. 31, 2012

Dec. 31, 2008

Dec. 31, 2008

Common Stock [Member]

Maximum [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Common Stock [Member]

Maximum [Member]

Minimum [Member]

Class of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of Series A Preferred Shares in Series A units

'

'

'

'

'

'

'

'

'

1

'

'

'

'

Warrants exercisable

'

'

'

'

'

'

'

'

'

$0.50

'

'

'

'

Total number of shares of common stock sold

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

1,000,000

Number of Warrants in Series A Units

'

'

'

'

'

'

'

'

'

2

'

'

'

'

Common stock value

$134,000

$1,000,000

$2,025,000

$87,000

'

'

'

'

'

'

$1,000,000

'

'

'

Convertible shares of common stock

'

'

'

'

$1

'

$0.15

'

'

'

$1

'

'

'

Common stock at market price on the first finance closing limit

'

'

'

'

'

'

'

'

'

'

1

'

'

'

Liquidation premium

'

'

'

'

'

'

'

'

6.00%

'

'

'

'

'

Conversion of convertible shares

'

'

'

'

'

2,000,000

'

500,000

'

'

'

2,000,000

'

'

Capital_Stock_Series_B_Preferr

Capital Stock - Series B Preferred Stock - Additional Information (Detail) (USD $)	9 Months Ended	145 Months Ended	1 Months Ended		3 Months Ended	1 Months Ended	3 Months Ended		9 Months Ended		3 Months Ended
	Sep. 30, 2012	Sep. 30, 2013	Jul. 19, 2013	31-May-08	31-May-08	31-May-08	Mar. 31, 2013	31-May-08	Sep. 30, 2013	Dec. 31, 2012	31-May-08
			Series B Warrants [Member]	Series B Warrants [Member]	Series B Warrants [Member]	Series B Preferred Stock [Member]	Series B Preferred Stock [Member]	Series B Preferred Stock [Member]	Series B Preferred Stock [Member]	Series B Preferred Stock [Member]	Series B Preferred Stock [Member]
											Common Stock [Member]
Class of Stock [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total number of shares of common stock sold	'	'	20,000,000	'	'	400,000	'	'	'	'	'
Number of Series A Preferred Shares in Series A units	'	'	'	'	'	1	'	'	'	'	'
Number of Warrants in Series A Units	'	'	'	2	'	'	'	'	'	'	'
Proceeds from issuance of preferred stock	$4,941,000	$17,202,000	'	'	'	'	'	$400,000	'	'	'
Conversion ratio for each share	'	'	'	'	0.25	'	'	0.5	'	'	2
Warrants exercisable	'	'	'	'	'	'	'	$0.50	'	'	'
Expiration date of warrants	'	'	24-Oct-13	'	'	'	'	31-Jul-13	'	'	'
Common stock issued upon conversion, conversion price per share	'	'	'	'	'	'	$0.20	'	'	'	'
Convertible Preferred Stock conversion price	'	'	'	'	'	'	'	'	$0.15	'	'
Liquidation premium	'	'	'	'	'	'	'	6.00%	'	'	'
Common stock, shares issued	'	'	'	'	'	'	'	'	300,000	300,000	'
Common stock, shares outstanding	'	'	'	'	'	'	'	'	300,000	300,000	'

Capital_Stock_Fair_Value_of_Wa

Capital Stock - Fair Value of Warrants Issued with Series A and B Preferred Stock - Additional Information (Detail) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

1 Months Ended

9 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2008

Dec. 31, 2006

Dec. 31, 2007

Jun. 30, 2010

Sep. 30, 2013

Dec. 31, 2008

Aug. 31, 2008

Aug. 31, 2008

Dec. 31, 2008

Jan. 15, 2008

Aug. 31, 2008

31-May-08

Dec. 31, 2007

Sep. 30, 2013

Dec. 31, 2007

Sep. 30, 2013

Sep. 30, 2013

Series A and Series B Preferred Stock [Member]

Series A and Series B Preferred Stock [Member]

Series A and Series B Preferred Stock [Member]

Series A and Series B Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Series A and Series B Preferred Stock [Member]

Series A and Series B Preferred Stock [Member]

Class of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Risk free interest rates

'

'

'

'

'

'

'

'

'

3.00%

'

'

'

'

'

'

'

3.00%

'

'

3.37%

Volatility rate minimum

0.00%

124.93%

118.34%

123.63%

'

'

'

'

57.90%

57.90%

'

'

'

'

'

'

63.00%

'

71.00%

'

'

Volatility rate maximum

'

'

'

'

'

'

'

'

65.00%

'

'

'

'

'

'

'

'

'

'

'

'

Expected option life-years based on management's estimate

'0 years

'5 years 7 months 6 days

'6 years 1 month 6 days

'5 years 8 months 12 days

'5 years

'

'

'

'5 years

'5 years

'

'

'

'

'

'

'5 years

'

'3 years

'

'

Exercise price

$0.15

'

$0.15

'

'

'

'

'

$0.50

'

$0.25

'

'

'

'

'

'

'

'

'

'

Convertible shares of common stock

'

'

'

'

'

'

$1

'

$1

'

'

'

'

$1

'

'

'

'

'

$0.15

'

Warrants exercisable

'

'

'

'

'

'

'

'

$0.25

'

'

'

$0.50

'

'

$0.50

'

'

'

'

'

Anti dilution provisions related to warrants and exercise price

'

'

'

'

'

'

'

$0.25

'

'

$0.25

'

'

'

'

'

'

'

'

'

'

Beneficial conversion feature

'

'

'

'

'

'

'

'

'

'

'

$553,000

'

'

$308,000

'

'

'

'

'

'

Warrants adjusted

0

36,000

0

73,000

'

638,000

'

804,971

'

'

'

193,000

'

'

110,000

'

'

'

'

'

'

Reduction in value of warrants due to revaluation

'

'

'

'

'

'

'

$5,276,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Capital_Stock_Series_C_Preferr

Capital Stock - Series C Preferred Stock - Additional Information (Detail) (USD $)	Dec. 31, 2007	Aug. 20, 2008	Dec. 31, 2008	Sep. 30, 2013	Jan. 22, 2013	Dec. 31, 2012	Sep. 23, 2008	Sep. 30, 2013
		Series C Preferred Stock [Member]	Series C Preferred Stock [Member]	Series C Preferred Stock [Member]	Series C Preferred Stock [Member]	Series C Preferred Stock [Member]	Series C Preferred Stock [Member]	Common Stock [Member]
Class of Stock [Line Items]	'	'	'	'	'	'	'	'
Total number of shares of common stock sold	'	3,000,000	'	'	'	'	'	'
Convertible shares of common stock	$1	$0.25	'	'	$0.25	'	'	'
Anti dilutive securities excluded from computation of earnings per share amount	'	'	250,000	'	'	'	'	'
Liquidation premium	'	'	6.00%	'	'	'	'	'
Number of Preferred Stock sold	'	700,000	'	'	'	'	1,300,000	'
Beneficial conversion feature	'	'	$720,000	'	'	'	'	'
Preferred Stock, shares outstanding	'	'	'	0	'	2,000,000	'	'
Conversion of convertible shares	'	'	'	'	'	'	'	8,000,000

Capital_Stock_Series_D_Preferr

Capital Stock - Series D Preferred Stock - Additional Information (Detail) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

145 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2012

Sep. 30, 2012

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2007

Sep. 30, 2013

31-May-08

Sep. 30, 2013

Mar. 31, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2009

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2008

Sep. 30, 2013

Jun. 30, 2013

Mar. 09, 2012

Mar. 31, 2013

Sep. 30, 2013

Sep. 30, 2012

Series D Preferred Stock [Member]

Series D Preferred Stock [Member]

Series D Preferred Stock [Member]

Series D Preferred Stock [Member]

Series D Preferred Stock [Member]

Series D Preferred Stock [Member]

Series D Preferred Stock [Member]

Series D Preferred Stock [Member]

Series D Preferred Stock [Member]

Series D Preferred Stock [Member]

Series D Preferred Stock [Member]

Series D Preferred Stock [Member]

Series G Preferred Stock [Member]

Series G Preferred Stock [Member]

Series G Preferred Stock [Member]

Series G Preferred Stock [Member]

Dr. Andrey Semechkin [Member]

X-Master Inc. [Member]

Class of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Secured Convertible Note amount

'

'

'

'

'

'

'

$1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock sold for an aggregate to aspire capital

'

'

'

'

'

1,200,000

'

'

'

'

'

'

'

'

'

'

5,000,000

'

'

'

'

'

'

Total number of shares of common stock sold

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50

'

'

'

'

'

'

Preferred stock price per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$100,000

'

'

'

'

'

'

Total amount raised

'

'

'

'

'

'

'

'

'

'

'

4,700,000

'

'

'

'

'

'

'

'

'

'

'

Total deemed dividend

'

'

'

'

-524,000

'

'

'

'

'

'

'

'

2,480,000

'

'

'

'

'

1,375,000

'

'

'

Preferred stock, shares issued

'

'

'

'

'

'

'

'

43

'

'

43

'

'

43

'

'

33

10

'

'

'

'

Rate of preferred stock dividend and redemption premium

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6.00%

10.00%

'

'

'

'

'

6.00%

'

Number of days with in dividend declared after each quarter end

'

'

'

'

'

'

'

'

'

'

'

'15 days

'

'

'15 days

'

'

'

'

'

'

'

'

Common stock issued upon conversion, conversion price per share

'

'

'

'

'

'

'

'

'

$0.20

'

'

'

'

'

'

'

'

'

'

$0.20

'

'

Payment of preferred stock dividends

'

237,000

'

'

'

'

1,320,000

'

0

'

64,000

0

237,000

'

'

'

'

'

'

'

'

0

0

Accrued dividend on preferred stock

($93,000)

$129,000

($222,000)

($430,000)

'

'

$8,097,000

'

'

'

'

$0

$0

'

$0

'

'

'

'

'

'

$0

$0

Capital_Stock_Series_E_Preferr

Capital Stock - Series E Preferred Stock - Additional Information (Detail) (USD $)

Mar. 12, 2013

Jan. 22, 2013

Sep. 30, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2008

Dec. 31, 2007

Dec. 31, 2006

Dec. 31, 2005

Dec. 31, 2004

Dec. 31, 2003

Dec. 31, 2002

Dec. 31, 2001

Aug. 31, 2001

Jun. 30, 2009

Dec. 31, 2010

Dec. 31, 2009

Jun. 30, 2009

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2009

Dec. 31, 2010

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Series E Preferred Stock [Member]

Series E Preferred Stock [Member]

Series E Preferred Stock [Member]

Series E Preferred Stock [Member]

Series E Preferred Stock [Member]

Series E Preferred Stock [Member]

Series E Preferred Stock [Member]

Series E Preferred Stock [Member]

Capital Partners LLC [Member]

Warrants [Member]

Maximum [Member]

Minimum [Member]

Common Stock [Member]

Warrants [Member]

Class of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Investment commitment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5,000,000

'

'

'

'

Number of years warrants to purchase common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

Percentage on warrants to purchase common stock of closing price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100.00%

'

'

'

'

'

'

'

Percentage of exercise value of warrants issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

135.00%

'

'

'

'

'

'

'

Rate of preferred stock dividend and redemption premium

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

Commitment fee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

250,000

'

'

'

'

'

'

'

Number of days for promptly file after the Effective Date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'30 days

'

'

'

'

'

Percentage of redemption premium

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

26.00%

0.00%

'

Private equity financing

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,400,000

'

'

'

'

'

'

Total number of shares of common stock sold

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

24

'

'

'

'

'

'

Warrant to purchase common stock

2,500,000

5,062,500

1,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,700,000

Shares, issued

'

'

134,169,000

87,389,000

80,036,000

74,771,000

56,035,000

38,411,000

35,370,000

33,997,000

'

'

'

'

'

'

'

'

'

'

3,700,000

'

'

'

Capital_Stock_Series_F_Preferr

Capital Stock - Series F Preferred Stock - Additional Information (Detail) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2008

Dec. 31, 2007

Mar. 12, 2013

Jan. 22, 2013

Dec. 31, 2007

Dec. 31, 2007

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2010

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Minimum [Member]

Maximum [Member]

Socius Exchange Agreement [Member]

Series F Preferred Stock [Member]

Series F Preferred Stock [Member]

Series F Preferred Stock [Member]

Perpetual Preferred Stock [Member]

Perpetual Preferred Stock [Member]

Perpetual Preferred Stock [Member]

Fee Shares [Member]

Socius CG II, Ltd. [Member]

Minimum [Member]

Maximum [Member]

Class of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock sold for an aggregate to aspire capital

'

'

'

'

'

$1,200,000

'

'

'

'

'

'

'

$10,000,000

'

'

'

Number of purchase agreement shares sold

'

'

'

'

'

'

'

'

'

'

'

1,000

'

'

'

'

'

Selling price per shares

'

'

'

'

'

'

'

'

'

'

'

$10,000

'

'

'

'

'

Shares, issued

'

'

'

'

'

'

'

'

'

'

'

'

250,000

'

'

'

'

Warrant to purchase common stock

'

'

'

'

'

'

2,500,000

5,062,500

'

'

'

7,000,000

'

'

'

'

'

Common stock exercise price per share

'

'

'

'

'

'

'

'

'

'

'

$1.93

'

'

'

'

'

Notes issued

'

'

'

'

'

'

'

'

'

'

2,500,000

'

'

'

'

'

'

Percentage of financing receivable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

135.00%

'

'

Note Receivable accrued interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.00%

'

'

Rate of preferred stock dividend and redemption premium

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

Risk free interest rates

0.00%

0.88%

0.95%

0.94%

'

'

'

'

4.58%

5.13%

'

'

'

'

2.40%

'

'

Risk-free interest rates maximum

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.65%

'

'

Volatility rate minimum

0.00%

124.93%

118.34%

123.63%

'

'

'

'

63.00%

71.00%

'

'

'

'

64.46%

'

'

Volatility rate maximum

'

'

'

'

'

'

'

'

'

'

'

'

'

'

65.33%

'

'

Period

'0 years

'5 years 7 months 6 days

'6 years 1 month 6 days

'5 years 8 months 12 days

'5 years

'

'

'

'5 years

'3 years

'

'

'

'

'5 years

'

'

Exercise price

$0.15

'

$0.15

'

'

'

'

'

'

'

'

'

'

'

'

$0.56

$0.74

Common stock liquidation preferences amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$15,000,000

'

'

Liquidation premium

'

'

'

'

'

'

'

'

'

'

'

'

'

'

26.00%

'

'

Capital_Stock_Series_G_Preferr

Capital Stock - Series G Preferred Stock - Additional Information (Detail) (USD $)

9 Months Ended

12 Months Ended

145 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

1 Months Ended

Sep. 30, 2012

Dec. 31, 2012

Dec. 31, 2010

Dec. 31, 2007

Sep. 30, 2013

Mar. 09, 2012

Sep. 30, 2013

Mar. 31, 2013

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Mar. 09, 2012

Series G Preferred Stock [Member]

Series G Preferred Stock [Member]

Series G Preferred Stock [Member]

Series G Preferred Stock [Member]

Series G Preferred Stock [Member]

Series G Preferred Stock [Member]

Series G Preferred Stock [Member]

Directors

Minimum [Member]

AR Partners, LLC [Member]

Changes In Equity And Comprehensive Income Line Items [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Number of purchase agreement shares sold

'

'

'

'

'

'

'

'

'

'

'

5,000,000

Selling price per shares

'

'

'

'

'

'

'

'

'

'

'

$1

Common stock sold for an aggregate to aspire capital

'

'

'

$1,200,000

'

'

'

'

'

'

'

$5,000,000

Convertible shares of common stock

'

'

'

$1

'

'

$0.40

'

$0.40

'

'

'

Initial conversion ratio of common stock

'

'

'

'

'

'

'

'

2.50%

'

'

'

Rate of preferred stock dividend and redemption premium

'

'

'

'

'

'

'

'

6.00%

'

'

'

Preferred Stock, shares outstanding

'

'

'

'

'

'

'

'

'

'

1,000,000

'

Number of directors to be nominated by preferred shareholders

'

'

'

'

'

'

'

'

2

'

'

'

Number of independent directors out of directors to be nominated by preferred shareholders

'

'

'

'

'

'

'

'

1

'

'

'

Reversal of dividend accreted

93,000

93,000

'

'

93,000

'

'

'

'

93,000

'

'

Legal costs

'

'

'

'

'

'

'

'

'

59,000

'

'

Total deemed dividend

'

'

($524,000)

'

'

$1,375,000

'

'

'

'

'

'

Common stock issued upon conversion, conversion price per share

'

'

'

'

'

'

'

$0.20

'

'

'

'

Convertible Preferred Stock conversion price

'

'

'

'

'

'

$0.30

$0.37

'

'

'

'

Convertible Preferred Stock conversion ratio

'

'

'

'

'

'

3.28

2.67

3.28

'

'

'

Capital_Stock_Common_Stock_Pur

Capital Stock - Common Stock Purchase Agreement and Registration Rights - Additional Information (Detail) (USD $)

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

145 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

1 Months Ended

Jul. 31, 2013

Jul. 19, 2013

Mar. 12, 2013

Jan. 22, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2008

Dec. 31, 2007

Sep. 30, 2013

Jul. 24, 2013

Dec. 31, 2006

Dec. 27, 2006

Dec. 31, 2007

Sep. 30, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Sep. 30, 2013

Jul. 19, 2013

Sep. 30, 2013

Jul. 19, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Jul. 24, 2013

Sep. 30, 2013

Sep. 30, 2013

Jul. 24, 2013

Mar. 12, 2013

Jan. 22, 2013

Jul. 19, 2013

Jul. 19, 2013

Sep. 30, 2013

Dec. 31, 2010

Dec. 09, 2010

Dec. 09, 2010

Dec. 09, 2010

Dec. 09, 2010

Dec. 09, 2010

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Jul. 19, 2013

Jul. 19, 2013

Jul. 19, 2013

Jul. 19, 2013

Jul. 19, 2013

Jul. 19, 2013

Jul. 19, 2013

Jul. 19, 2013

Jul. 19, 2013

Maximum [Member]

Maximum [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

U.S. Treasury Notes [Member]

U.S. Treasury Notes [Member]

U.S. Treasury Notes [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Co-Chairman and Chief Executive Officer [Member]

Co-Chairman and Chief Executive Officer [Member]

Dr. Andrey Semechkin and Ruslan Semechkin [ Member]

Placement Agent Warrants [Member]

Placement Agent Warrants [Member]

Common Stock Purchase Agreement [Member]

Common Stock Purchase Agreement [Member]

Common Stock Purchase Agreement [Member]

Common Stock Purchase Agreement [Member]

Common Stock Purchase Agreement [Member]

Common Stock Purchase Agreement [Member]

Registration Rights [Member]

Registration Rights [Member]

Registration Rights [Member]

Registration Rights [Member]

Subscription Agreements [Member]

Subscription Agreements [Member]

Subscription Agreements [Member]

Subscription Agreements [Member]

Subscription Agreements [Member]

Subscription Agreements [Member]

Subscription Agreements [Member]

Subscription Agreements [Member]

Subscription Agreements [Member]

Series A Warrants [Member]

Series B Warrants [Member]

Aspire Capital Fund, LLC [Member]

Aspire Capital Fund, LLC [Member]

Aspire Capital Fund, LLC [Member]

Aspire Capital Fund, LLC [Member]

Aspire Capital Fund, LLC [Member]

Aspire Capital Fund, LLC [Member]

Aspire Capital Fund, LLC [Member]

Aspire Capital Fund, LLC [Member]

Aspire Capital Fund, LLC [Member]

Aspire Capital Fund, LLC [Member]

Units [Member]

Common Stock [Member]

Series A Warrants [Member]

Series B Warrants [Member]

Units and Series B Warrants [Member]

Co-Chairman and Chief Executive Officer [Member]

Co-Chairman and Chief Executive Officer [Member]

Company's Chief Science Officer [Member]

Company's Chief Science Officer [Member]

Closing Price is above $ 0.25 [Member]

Closing Price is above $ 1.25 [Member]

Closing Price is above $ 1.75 [Member]

Closing Price is above $ 2.25 [Member]

Units [Member]

Series B Warrants [Member]

Units [Member]

Series B Warrants [Member]

Changes In Equity And Comprehensive Income Line Items [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock value

'

'

$1,000,000

$2,025,000

$134,000

'

$134,000

'

$87,000

'

'

'

'

'

$134,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$25,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of purchase agreement shares sold

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

333,333

'

'

'

'

'

'

'

'

20,000,000

'

'

20,000,000

'

'

'

'

'

Common stock sold for an aggregate to aspire capital

'

'

'

'

'

'

'

'

'

'

'

'

'

1,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Capital commitment fees on common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock purchase agreement period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of days to be taken for calculation shares sales price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'12 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, share issued

'

'

5,000,000

10,125,000

134,169,565

'

134,169,565

'

87,388,815

'

'

'

'

1,370,000

134,169,565

'

1,350,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,000,000

'

'

'

'

'

'

'

'

'

'

100,000

150,000

200,000

300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Closing price of common shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.25

$1.25

$1.75

$2.25

'

'

'

'

'

'

'

'

'

'

'

'

'

Issued shares to Aspire Capital for operating activities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

1,200,000

5,000,000

'

'

'

'

'

'

'

'

'

Issued to aspire capital for operating activities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

264,000

2,100,000

'

'

'

'

'

'

'

'

'

Common stock value per share

'

'

$0.20

$0.20

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of warrant period from which warrants exercisable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of shares purchased after exercising warrants

'

'

50.00%

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued

'

'

2,500,000

5,062,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,700,000

'

'

'

'

'

'

'

'

'

'

1,700,000

20,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,998,999

'

667,667

Number of shares/Warrants included in total Units

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,000,000

20,000,000

'

'

5,998,999

'

667,667

'

Common stock, par value

'

$0.00

'

'

$0.00

'

$0.00

'

$0.00

'

'

'

'

'

$0.00

'

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exercise price

'

'

0.2

0.2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.15

'

'

0.15

'

'

'

0.15

'

'

'

'

'

'

'

'

'

'

'

'

'

0.15

'

'

'

'

'

'

Gross proceeds from sale of units

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,000,000

'

'

'

'

Proceeds from stock offering

'

2,400,000

'

'

'

'

6,289,000

2,088,000

2,084,000

3,358,000

10,190,000

1,400,000

'

'

35,171,000

'

'

'

'

'

5,000

4,000

10,000

3,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of agent fee on gross proceeds from Offering

'

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum amount of reimbursement payable to agent

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

75,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants issued

'

'

'

'

'

'

49,929,166

'

'

200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

666,666

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of agent warrants to purchase on units issued in offering

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants, term

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'65 days

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of Agent cash solicitation fee on gross proceeds

'

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exercise price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expiration date of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

24-Oct-13

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exercise

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,700,000

'

'

'

'

'

1,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from issuance of common stock and warrants

2,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

242,000

'

'

'

'

'

242,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock price

'

'

'

'

$0.15

'

$0.15

'

'

'

'

'

'

'

$0.15

'

'

'

'

$0.15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant exercise price

'

'

'

'

$0.15

'

$0.15

'

'

'

'

'

'

'

$0.15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock price volatility

'

'

'

'

'

'

87.70%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Risk free interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.03%

1.33%

1.33%

0.03%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant expiration term

'

'

'

'

'0 years

'5 years 7 months 6 days

'6 years 1 month 6 days

'5 years 8 months 12 days

'

'

'

'

'5 years

'

'

'

'

'

'3 years

'

'

'

'

'

'

'

'5 years

'

'

'26 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants description

'

'

'

'

'

'

'Monte-Carlo simulation method

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of warrant liability in excess of proceeds

'

'

'

'

1,390,000

'

1,390,000

'

'

'

'

'

'

'

1,390,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of warrants at issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,720,000

'

2,650,000

2,650,000

'

'

'

'

'

'

'

'

'

'

'

115,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant liabilities

'

'

'

'

4,400,000

'

4,400,000

'

'

'

'

'

'

'

4,400,000

4,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Change in fair value of warrants

'

'

'

'

27,000

'

27,000

38,000

'

'

'

'

'

'

-1,330,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Transaction financing costs

'

'

'

'

738,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other expense

'

'

'

'

$2,096,000

$1,000

$2,103,000

$10,000

'

'

'

'

'

'

$5,613,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Capital_Stock_Summary_of_Share

Capital Stock - Summary of Shares of Common Stock Reserved for Future Issuance (Detail)	Sep. 30, 2013	Sep. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Shares of common stock reserved for future issuance net	147,022,156	'
Options Outstanding [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Shares of common stock reserved for future issuance net	23,694,693	'
Options Available for Future Grant [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Shares of common stock reserved for future issuance net	16,032,480	'
Convertible Preferred Stock [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Shares of common stock reserved for future issuance net	39,899,151	'
Warrants [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Shares of common stock reserved for future issuance net	67,395,832	3,530,000

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended		145 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Sep. 30, 2013
Related Party Transaction Due From To Related Party [Line Items]	'	'	'	'	'	'	'
Dividend to preferred stock	'	($93,000)	'	$129,000	($222,000)	($430,000)	$8,097,000
Reversal of dividend accreted	'	'	'	93,000	93,000	'	93,000
Accrued dividend paid	'	'	0	'	'	'	'
Rent expense related to facility lease arrangement	39,000	29,000	118,000	86,000	'	'	'
Series G Preferred Stock [Member]	'	'	'	'	'	'	'
Related Party Transaction Due From To Related Party [Line Items]	'	'	'	'	'	'	'
Dividend to preferred stock	'	'	0	0	'	'	'
Reversal of dividend accreted	'	'	'	'	93,000	'	'
Series D Preferred Stock [Member]	'	'	'	'	'	'	'
Related Party Transaction Due From To Related Party [Line Items]	'	'	'	'	'	'	'
Dividend to preferred stock	'	'	$0	$0	$0	'	'

Stock_Options_and_Warrants_Add

Stock Options and Warrants - Additional Information (Detail) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2008

Mar. 12, 2013

Jan. 22, 2013

Dec. 31, 2007

Dec. 31, 2008

Dec. 31, 2007

Dec. 31, 2007

Mar. 31, 2007

Dec. 31, 2007

Mar. 31, 2007

Dec. 31, 2007

Dec. 31, 2006

Dec. 31, 2007

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2010

Sep. 30, 2013

Dec. 31, 2012

Dec. 31, 2009

Sep. 30, 2013

Private placement [Member]

Private placement [Member]

Maximum [Member]

Minimum [Member]

Individuals [Member]

Individuals [Member]

Brookstreet [Member]

Brookstreet [Member]

Brookstreet [Member]

Brookstreet [Member]

2006 Plan [Member]

2010 Plan [Member]

2010 Plan [Member]

2006 Plan and 2010 Plan [Member]

2006 Plan and 2010 Plan [Member]

2006 Plan and 2010 Plan [Member]

2006 Plan and 2010 Plan [Member]

Private placement [Member]

Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options granted to employees, directors and consultants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,000,000

'

18,000,000

1,352,500

2,398,000

10,257,593

'

Expiry of options

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'10 years

'

'10 years

'

'

'

Options vesting terms

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'50 months

'

'

'

Stock-based compensation expense

$442,000

$534,000

$1,300,000

$1,800,000

'

'

'

'

'

'

'

'

$222,000

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation expense related to stock options

2,300,000

4,400,000

2,300,000

4,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average period

'1 year 8 months 12 days

'2 years 4 months 24 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

Compensation received as warrants

5,780,175

'

5,780,175

'

'

'

'

'

'

'

'

'

'

'

'

1,976,190

'

'

'

'

'

'

'

'

Additional warrants earned

'

'

'

'

'

'

'

274,000

'

'

'

426,767

'

274,000

2,250,190

'

'

'

'

'

'

'

'

'

Warrant exercised

'

'

'

'

'

0.2

0.2

1

0.56

'

'

'

0.8

'

'

'

1

'

'

'

'

'

'

'

Non-cash offering cost

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,200,000

'

'

'

'

'

'

'

'

'

Private equity placement total

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9,900,000

'

'

'

'

'

'

'

'

'

Cash offering costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,500,000

'

'

'

'

'

'

'

'

'

Period

'0 years

'5 years 7 months 6 days

'6 years 1 month 6 days

'5 years 8 months 12 days

'5 years

'

'

'

'

'3 years

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

Risk free interest rates

0.00%

0.88%

0.95%

0.94%

'

'

'

'

'

5.13%

4.58%

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividend yield

0.00%

0.00%

0.00%

0.00%

0.00%

'

'

'

'

0.00%

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Volatility rate minimum

0.00%

124.93%

118.34%

123.63%

'

'

'

'

'

71.00%

63.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock_Options_and_Warrants_Fai

Stock Options and Warrants - Fair Value of Stock Option Award (Detail)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2008
Significant assumptions (weighted-average):	'	'	'	'	'
Risk-free interest rate at grant date	0.00%	0.88%	0.95%	0.94%	'
Expected stock price volatility	0.00%	124.93%	118.34%	123.63%	'
Expected dividend payout	0.00%	0.00%	0.00%	0.00%	0.00%
Expected option life-years based on management's estimate	'0 years	'5 years 7 months 6 days	'6 years 1 month 6 days	'5 years 8 months 12 days	'5 years

Stock_Options_and_Warrants_Sum

Stock Options and Warrants - Summary of Changes in Options Outstanding and Related Exercise Prices (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding, Number Outstanding	23,694,693
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	'6 years 5 months 27 days
Options Outstanding, Weighted Average Exercise Price	$0.96
Options Exercisable and vested, Number Exercisable	17,914,518
Options Exercisable and vested, Weighted Average Remaining Contractual Life (Years)	'6 years 7 days
Options Exercisable and vested, Weighted Average Exercise Price	$0.96
$0.22-$0.50 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding Exercise Prices, Lower Range Limit	$0.22
Options Outstanding Exercise Prices, Upper Range Limit	$0.50
Options Outstanding, Number Outstanding	5,198,300
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	'7 years 3 months 22 days
Options Outstanding, Weighted Average Exercise Price	$0.37
Options Exercisable and vested, Number Exercisable	2,612,100
Options Exercisable and vested, Weighted Average Remaining Contractual Life (Years)	'5 years 6 months 22 days
Options Exercisable and vested, Weighted Average Exercise Price	$0.42
$0.51-$0.75 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding Exercise Prices, Lower Range Limit	$0.51
Options Outstanding Exercise Prices, Upper Range Limit	$0.75
Options Outstanding, Number Outstanding	9,265,293
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	'6 years 2 months 5 days
Options Outstanding, Weighted Average Exercise Price	$0.62
Options Exercisable and vested, Number Exercisable	8,363,918
Options Exercisable and vested, Weighted Average Remaining Contractual Life (Years)	'6 years 1 month 24 days
Options Exercisable and vested, Weighted Average Exercise Price	$0.62
$0.76-$1.00 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding Exercise Prices, Lower Range Limit	$0.76
Options Outstanding Exercise Prices, Upper Range Limit	$1
Options Outstanding, Number Outstanding	1,895,000
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	'3 years 9 months 7 days
Options Outstanding, Weighted Average Exercise Price	$0.98
Options Exercisable and vested, Number Exercisable	1,791,000
Options Exercisable and vested, Weighted Average Remaining Contractual Life (Years)	'3 years 6 months 7 days
Options Exercisable and vested, Weighted Average Exercise Price	$0.99
$1.01-$1.25 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding Exercise Prices, Lower Range Limit	$1.01
Options Outstanding Exercise Prices, Upper Range Limit	$1.25
Options Outstanding, Number Outstanding	335,000
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	'7 years 7 months 2 days
Options Outstanding, Weighted Average Exercise Price	$1.10
Options Exercisable and vested, Number Exercisable	253,600
Options Exercisable and vested, Weighted Average Remaining Contractual Life (Years)	'7 years 7 months 2 days
Options Exercisable and vested, Weighted Average Exercise Price	$1.10
$1.26-$1.50 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding Exercise Prices, Lower Range Limit	$1.26
Options Outstanding Exercise Prices, Upper Range Limit	$1.50
Options Outstanding, Number Outstanding	1,171,100
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	'6 years 4 months 13 days
Options Outstanding, Weighted Average Exercise Price	$1.31
Options Exercisable and vested, Number Exercisable	926,700
Options Exercisable and vested, Weighted Average Remaining Contractual Life (Years)	'6 years 2 months 27 days
Options Exercisable and vested, Weighted Average Exercise Price	$1.32
$1.51-$3.20 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding Exercise Prices, Lower Range Limit	$1.51
Options Outstanding Exercise Prices, Upper Range Limit	$3.20
Options Outstanding, Number Outstanding	5,830,000
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	'7 years 29 days
Options Outstanding, Weighted Average Exercise Price	$1.94
Options Exercisable and vested, Number Exercisable	3,967,200
Options Exercisable and vested, Weighted Average Remaining Contractual Life (Years)	'7 years
Options Exercisable and vested, Weighted Average Exercise Price	$1.95

Stock_Options_and_Warrants_Sum1

Stock Options and Warrants - Summary of the Changes in Options Outstanding and the Related Exercise Prices for the Shares of the Company's Common Stock Options Issued (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Sep. 30, 2013	Dec. 31, 2011	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2009
						Outside Plan [Member]	Outside Plan [Member]	2006 Plan and 2010 Plan [Member]	2006 Plan and 2010 Plan [Member]	2006 Plan and 2010 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'	'	'
Number of Shares, Outstanding, Beginning balance	48,429,166	3,500,000	6,569,550	6,670,878	9,565,552	8,254,232	8,254,232	15,122,900	14,730,207	'
Number of Shares, Granted	'	'	'	'	'	'	'	1,352,500	2,398,000	10,257,593
Number of Shares, Exercised	'	'	'	'	'	'	'	'	-17,500	'
Number of Shares, Canceled or expired	'	'	'	'	'	-644,939	'	-390,000	-1,987,807	'
Number of Shares, Outstanding, Ending balance	48,429,166	3,500,000	6,569,550	6,670,878	9,565,552	7,609,293	8,254,232	16,085,400	15,122,900	'
Weighted Average Exercise Price Per Share, Outstanding, Beginning balance	'	'	'	'	'	$0.65	$0.65	$1.18	$1.26	'
Weighted Average Exercise Price Per Share, Granted	'	'	'	'	'	'	'	$0.27	$0.38	'
Weighted Average Exercise Price Per Share, Exercised	'	'	'	'	'	'	'	'	$0.22	'
Weighted Average Exercise Price Per Share, Canceled or expired	'	'	'	'	'	$1	'	$0.56	$0.78	'
Weighted Average Exercise Price Per Share, Outstanding, Ending balance	'	'	'	'	'	$0.62	$0.65	$1.12	$1.18	'

Stock_Options_and_Warrants_Add1

Stock Options and Warrants - Additional Information1 (Detail) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

9 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2008

Dec. 31, 2007

Mar. 12, 2013

Jan. 22, 2013

Dec. 31, 2012

Dec. 31, 2006

Dec. 31, 2008

Dec. 31, 2007

Dec. 31, 2009

Dec. 31, 2008

Dec. 31, 2006

Dec. 31, 2008

Mar. 31, 2007

Sep. 30, 2013

Dec. 31, 2007

Dec. 31, 2011

Dec. 31, 2008

Dec. 31, 2009

Dec. 31, 2007

Sep. 30, 2013

Jan. 31, 2013

Dec. 31, 2010

Dec. 31, 2008

Dec. 31, 2008

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Dec. 31, 2008

Sep. 30, 2013

Warrants to Purchase Shares of Common Stock [Member]

Private placement [Member]

Private placement [Member]

Private placement [Member]

Private placement [Member]

Minimum [Member]

Brookstreet [Member]

Brookstreet [Member]

Brookstreet [Member]

Brookstreet [Member]

Brookstreet [Member]

Brookstreet [Member]

Brookstreet [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

YKA Loan [Member]

Private placement [Member]

Private placement [Member]

Warrants Issued with Preferred Stock [Member]

Warrants Issued with Preferred Stock [Member]

Warrants Issued with Preferred Stock [Member]

Warrants to Purchase Shares of Common Stock [Member]

Warrants Issued with Preferred Stock [Member]

Warrants Issued with Preferred Stock [Member]

Warrants Issued with Preferred Stock [Member]

Warrants [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants converted into common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

484,675

'

'

612,267

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares issued

134,169,565

'

134,169,565

'

'

1,370,000

5,000,000

10,125,000

87,388,815

1,350,000

1,100,000

'

484,675

'

'

'

'

'

'

'

'

3,510,206

1,370,000

'

'

800,000

1

'

'

'

'

1

'

Net of cash fees and expenses

'

'

'

'

'

$1,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional warrants earned

'

'

'

'

'

'

'

'

'

'

'

274,000

'

'

'

'

274,000

'

2,250,190

'

'

'

'

'

'

'

'

'

'

'

'

'

1,400,000

Warrant exercised

'

'

'

'

'

'

0.2

0.2

'

'

'

1

'

0.56

'

'

'

'

'

'

'

'

1

'

'

'

'

'

'

'

0.2

'

0.25

Deemed dividend

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

337,000

'

'

'

'

'

'

'

'

'

'

'

'

Value attributable to the warrants

74,967,000

'

74,967,000

'

'

'

'

'

69,945,000

'

'

169,000

'

'

1,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period

'0 years

'5 years 7 months 6 days

'6 years 1 month 6 days

'5 years 8 months 12 days

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Risk free interest rates

0.00%

0.88%

0.95%

0.94%

'

'

'

'

'

'

'

'

'

'

'

4.58%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividend yield

0.00%

0.00%

0.00%

0.00%

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Volatility rate minimum

0.00%

124.93%

118.34%

123.63%

'

'

'

'

'

'

'

'

'

'

'

70.57%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant revalued

'

'

'

'

0.56

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant per share

0.25

'

0.25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant liabilities

'

0

'

0

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Recorded income

0

0

0

38,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Brookstreet Warrants outstanding

'

'

'

'

'

'

'

'

'

'

1,100,000

'

'

'

'

'

'

'

'

1,721,629

'

'

'

'

1,600,000

400,000

2

2,000,000

'

0

300,000

2

'

Fair market value of the warrants

'

'

'

$38,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expiry date of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

14-Feb-12

'

'

'

'

'

31-Jan-13

'

'

'

'

31-Jul-13

'

'

'

'

Stock_Options_and_Warrants_Add2

Stock Options and Warrants - Additional Information2 (Detail) (USD $)

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

145 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

12 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

9 Months Ended

Jul. 24, 2013

Jul. 31, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2011

Dec. 31, 2008

Sep. 30, 2013

Mar. 12, 2013

Jan. 22, 2013

Dec. 31, 2012

Dec. 31, 2007

Dec. 31, 2006

Dec. 31, 2007

Dec. 31, 2007

Sep. 30, 2013

Jul. 24, 2013

Sep. 30, 2013

Sep. 30, 2013

Jul. 24, 2013

Sep. 30, 2013

Jul. 19, 2013

Sep. 30, 2013

Sep. 30, 2013

Jul. 19, 2013

Sep. 30, 2013

Sep. 30, 2013

Jul. 24, 2013

Sep. 30, 2013

Jul. 19, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2011

Dec. 31, 2011

Dec. 31, 2008

Sep. 30, 2012

Jun. 30, 2008

Dec. 31, 2011

Sep. 30, 2011

Dec. 31, 2011

Sep. 30, 2013

Jan. 15, 2008

Jan. 31, 2013

Dec. 31, 2010

Dec. 31, 2008

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Dec. 31, 2008

Minimum [Member]

Maximum [Member]

Maximum [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Common Stock [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Placement Agent Warrants [Member]

Placement Agent Warrants [Member]

U.S. Treasury Notes [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Bio Time [Member]

Bio Time [Member]

Bio Time [Member]

Bio Time [Member]

Bio Time [Member]

Bio Time [Member]

Bio Time [Member]

Bio Time [Member]

Bio Time [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

U.S. Treasury Notes [Member]

U.S. Treasury Notes [Member]

Tranches

Minimum [Member]

Maximum [Member]

Maximum [Member]

Warrants Issued with Preferred Stock [Member]

Warrants Issued with Preferred Stock [Member]

Warrants Issued with Preferred Stock [Member]

Warrants Issued with Preferred Stock [Member]

Warrants Issued with Preferred Stock [Member]

Warrants Issued with Preferred Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Brookstreet Warrants outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

30,000

'

'

'

'

'

1,600,000

400,000

2

'

0

300,000

2

Warrant exercised

'

'

'

'

'

'

'

'

'

0.2

0.2

'

'

'

'

'

'

0.15

'

'

0.15

'

0.15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.25

'

'

'

'

'

'

'

'

'

'

0.2

'

Expiry date of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

24-Oct-13

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

31-Dec-12

'

'

'

'

'

31-Jan-13

'

'

'

'

31-Jul-13

'

'

'

Sale of common stock

'

'

134,169,565

'

134,169,565

'

'

'

134,169,565

5,000,000

10,125,000

87,388,815

1,370,000

1,350,000

'

'

'

20,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

800,000

1

'

'

'

1

Shares issued

'

'

'

'

'

'

'

'

'

2,500,000

5,062,500

'

'

'

'

'

'

'

'

1,700,000

20,000,000

1,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of warrant or right term

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'65 days

'

'

'

'

'5 years

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of units issued

20,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maturity term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exercise price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Closing bid price of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

80.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants expiration date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

24-Oct-13

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of warrants exercised

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from issuance of common stock and warrants

'

$2,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$242,000

'

'

'

'

'

'

'

$242,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock price

'

'

$0.15

'

$0.15

'

'

'

$0.15

'

'

'

'

'

'

'

$0.15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant exercise price

'

'

$0.15

'

$0.15

'

'

'

$0.15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock price volatility

'

'

'

'

87.70%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Risk free interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.33%

'

'

0.03%

'

0.03%

'

'

1.33%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period

'

'

'0 years

'5 years 7 months 6 days

'6 years 1 month 6 days

'5 years 8 months 12 days

'

'5 years

'

'

'

'

'

'

'5 years

'3 years

'

'

'

'

'

'

'

'

'

'

'

'26 days

'

'

'

'5 years

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Capital raised on stock issuance per share

'

'

'

'

'

'

'

'

'

'

'

'

$1

'

'

'

$0.15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1

'

'

'

'

'

'

'

Warrants description

'

'

'

'

'Monte-Carlo simulation method

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of warrant liability in excess of proceeds

'

'

1,390,000

'

1,390,000

'

'

'

1,390,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of warrants at issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

115,000

'

'

2,650,000

2,650,000

'

'

'

1,720,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant liabilities

4,500,000

'

4,400,000

'

4,400,000

'

'

'

4,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Change in fair value of warrants

'

'

27,000

'

27,000

38,000

'

'

-1,330,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Advance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$250,000

'

'

'

'

'

'

'

'

'

'

'

'

Number of tranches of common stock warrants issuable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares which can be purchased by the exercise of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Strike prices

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

1.5

2

'

'

'

'

'

'

'

'

'

'

Vesting over four quarters

'

'

'

'

'

'

'Four quarters

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options vesting terms

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

Number of warrants vested during period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Risk free interest rates

'

'

0.00%

0.88%

0.95%

0.94%

'

'

'

'

'

'

'

'

4.58%

5.13%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividend yield

'

'

0.00%

0.00%

0.00%

0.00%

'

0.00%

'

'

'

'

'

'

0.00%

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Volatility rate minimum

'

'

0.00%

124.93%

118.34%

123.63%

'

'

'

'

'

'

'

'

63.00%

71.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

134.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock_Options_and_Warrants_Sum2

Stock Options and Warrants - Summary of Outstanding Warrants Related to Warrant Transactions (Detail) (USD $)

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

Sep. 30, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Sep. 30, 2013

Dec. 31, 2010

Dec. 31, 2011

Sep. 30, 2013

Dec. 31, 2011

Dec. 31, 2010

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2012

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2011

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Sep. 30, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series A Common Stock [Member]

Series B Common Stock [Member]

Placement Agent Member

YKA Loan [Member]

YKA Loan [Member]

YKA Loan [Member]

YKA Loan [Member]

Bio Time [Member]

Bio Time [Member]

Bio Time [Member]

Bridge Loan & Non-cash Grants [Member]

Bridge Loan & Non-cash Grants [Member]

Bridge Loan & Non-cash Grants [Member]

Brookstreet [Member]

Brookstreet [Member]

Brookstreet [Member]

Skin Care Marketing [Member]

Skin Care Marketing [Member]

Skin Care Marketing [Member]

Jan 2013 Financing [Member]

Mar 2013 Financing [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of Shares, Outstanding, Beginning balance

3,500,000

6,569,550

6,670,878

9,565,552

1,600,000

2,000,000

1,600,000

300,000

500,000

1,100,000

'

'

'

1,400,000

1,400,000

1,400,000

1,400,000

30,000

30,000

30,000

1,317,921

1,380,721

1,629,623

1,721,629

1,760,157

3,405,929

'

200,000

200,000

'

'

'

'

'

'

'

'

'

'

Weighted Average exercise price, Issued

$0.16

'

$1.75

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.15

'

$1.50

'

$0.20

'

$2

'

Warrants, Issued

49,929,166

'

200,000

'

'

'

'

'

'

'

21,700,000

20,000,000

666,666

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

'

5,062,500

2,500,000

'

'

'

'

'

'

'

'

Warrants, Exercised

-1,700,000

'

-301,328

-2,894,674

'

-400,000

'

'

-200,000

-600,000

'

-1,700,000

'

'

'

'

'

'

'

'

'

-62,800

-248,902

'

-38,528

-1,645,772

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants, Forfeited/Cancelled

-3,300,000

-3,069,550

'

'

-1,600,000

'

'

-300,000

'

'

'

'

'

-1,400,000

'

'

'

-30,000

'

'

-1,317,921

'

'

-1,721,629

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of Shares, Outstanding, Ending balance

48,429,166

3,500,000

6,569,550

6,670,878

'

1,600,000

1,600,000

'

300,000

500,000

21,700,000

18,300,000

666,666

'

1,400,000

1,400,000

1,400,000

'

30,000

30,000

'

1,317,921

1,380,721

'

1,721,629

1,760,157

200,000

200,000

200,000

5,062,500

2,500,000

'

'

'

'

'

'

'

'

Weighted Average exercise price, Outstanding, Beginning balance

$0.34

$0.49

$0.45

$0.45

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.25

$0.25

$0.25

$0.25

$0.20

$2

$0.80

$0.80

Weighted Average exercise price, Exercised

$0.15

'

$0.40

$0.47

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0

'

$0.25

$0.25

$0.15

'

$0.80

$0.80

Weighted Average exercise price, Forfeited/Cancelled

$0.25

$0.66

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.20

$0.56

'

'

$0.25

$0.80

'

'

Weighted average exercise price, Outstanding, Ending balance

$0.16

$0.34

$0.49

$0.45

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.15

$0.25

$0.25

$0.25

$0.20

$0.20

$2

$0.80

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

145 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2006

Sep. 30, 2013

Jul. 31, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Jul. 31, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Tranches

Skin Care [Member]

Skin Care [Member]

Skin Care [Member]

Skin Care [Member]

Sales [Member]

Sales [Member]

Sales [Member]

Sales [Member]

Sales [Member]

Sales [Member]

Sales [Member]

Sales [Member]

Sales [Member]

Oceanside [Member]

Priestly Drive [Member]

Frederick [Member]

Skin Care [Member]

Skin Care [Member]

Skin Care [Member]

Skin Care [Member]

Skin Care [Member]

Skin Care [Member]

Skin Care [Member]

Skin Care [Member]

Skin Care [Member]

sqft

sqft

Major customer 1 [Member]

Major customer 1 [Member]

Major customer 1 [Member]

Major customer 1 [Member]

Major customer 2 [Member]

Major customer 2 [Member]

Major customer 2 [Member]

Major customer 2 [Member]

Commitments And Contingencies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Square feet of leased office and laboratory

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,215

4,653

'

Current base rent

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$8,588

$11,492

$11,644

Expiry of lease

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

31-Aug-16

29-Feb-16

31-Dec-15

Percentage of increase in monthly base rent

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.00%

3.00%

'

Expiry of lease additional

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'5 years

Initial monthly base rent

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,118

'

Percentage of net profits generated from the proprietary mailings

'

'

40.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of net revenues for Direct Sales generated from the proprietary mailings

'

'

20.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of net revenues for Referral Sales

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Termination of the agreement

'

'

'30 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Tranches of common stock

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock warrants to be issued for the benefit of the third party marketing organization

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Strike prices, tranche one

'

'

$1.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Strike prices, tranche two

'

'

$2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant term

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of revenue

'

'

'

'

'

'

'

'

'

'

'

18.00%

24.00%

17.00%

18.00%

15.00%

13.00%

13.00%

12.00%

10.00%

'

'

'

Percentage on net revenue derived from referral sales

'

'

'

'

'

'

9.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants issued for services

0

36,000

0

73,000

638,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Marketing expenses

$632,000

$477,000

$1,823,000

$1,521,000

'

$7,762,000

'

$18,000

$32,000

$61,000

$117,000

'

'

'

'

'

'

'

'

'

'

'

'

Commitments_and_Contingencies_2

Commitments and Contingencies - Summary of Future Minimum Lease Payments Required under Operating Leases that Have Initial or Remaining Non-Cancelable Lease Terms in Excess of One Year (Detail) (USD $)	Sep. 30, 2013
In Thousands, unless otherwise specified
Commitments And Contingencies Disclosure [Abstract]	'
2013 (remaining three months)	$97
2014	386
2015	397
2016	101
2017	3
Total	$984

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (USD $)

1 Months Ended

9 Months Ended

12 Months Ended

145 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

1 Months Ended

Jul. 24, 2013

Jul. 19, 2013

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Sep. 30, 2013

Mar. 12, 2013

Jan. 22, 2013

Jul. 19, 2013

Jul. 24, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Sep. 30, 2013

Jul. 19, 2013

Oct. 24, 2013

Oct. 17, 2013

Oct. 31, 2013

Sep. 30, 2013

Jul. 31, 2013

Jul. 31, 2013

Oct. 24, 2013

Oct. 31, 2013

Oct. 31, 2013

Oct. 31, 2013

Series B Warrants [Member]

Series B Warrants [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Dr. Andrey Semechkin and Ruslan Semechkin [ Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Common Stock [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Co-Chairman and Chief Executive Officer [Member]

Company's Chief Science Officer [Member]

Dr. Andrey Semechkin and Ruslan Semechkin [ Member]

Series B Warrants [Member]

Series B Warrants [Member]

Subsequent Event [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional net proceeds from issuance of common stock and warrants

'

'

$242,000

'

'

'

'

'

$1,234,000

'

'

'

'

'

'

'

'

'

'

'

'

$2,100,000

'

'

'

'

'

'

'

Number of warrants exercised

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,750,000

15,054,822

12,304,822

'

'

'

'

'

'

Number of warrants issued

20,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,054,822

'

'

'

'

'

Number of shares\Warrants included in total additional units

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,054,822

'

'

'

'

Warrant to exercised common stock

'

'

'

'

'

'

'

'

'

2,500,000

5,062,500

'

'

'

'

'

'

1,700,000

'

'

'

'

'

'

'

'

2,754,821

667,667

'

Proceeds from stock offering

'

2,400,000

6,289,000

2,088,000

2,084,000

3,358,000

10,190,000

1,400,000

35,171,000

'

'

'

'

5,000

4,000

10,000

3,000

'

1,000,000

'

'

'

'

'

'

'

'

'

497,000

Closing bid price of common stock

'

'

'

'

'

'

'

'

'

'

'

'

80.00%

'

'

'

'

'

'

'

20.00%

'

'

'

'

'

'

'

'

Closing bid price per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.18

'

'

'

'

'

'

'

'

Adjusted exercise price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.15

'

'

'

'

'

'

'

'

Proceeds form warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,700,000

'

$400,000

'

'

'

'

'

'

Warrants exercise price

'

'

'

'

'

'

'

'

'

'

'

$0.15

'

'

'

'

'

'

'

'

$0.15

'

'

'

'

'

'

'

'

Warrants expiration date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'October 24th

'

'

'

'

'

'

Warrants expired unexercised

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,245,178

'

'

'

'

'

'

'

'

'

Warrants outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

45,183,988

'

'

'

'

'

'

'

'

'

Common stock reserved for future issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

45,850,654

'

'

'

'

'

'

'

'

'

Outstanding warrants exercisable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

36,754,822

'

'

'